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ABSTRACT 
 
It has been shown that the amino terminus and second extracellular loop 
(EC2) of CXCR2 are crucial for ligand binding and receptor activation. The lack 
of an ionic lock motif in the third intracellular loop of CXCR2 focuses an 
investigation of the mechanism by which these two extracellular regions 
contribute to receptor recognition and activation.  
The first objective of this investigation was to predict the structure of 
CXCR2 based on known structures of crystallized GPCRs. Rhodopsin, β2-
adrenergic receptor, CXCR4 were used for homology modeling of CXCR2 
structure. Highly conserved motifs found in sequence alignments of the template 
GPCRs were helpful to generate CXCR2 models. We also studied solvent 
accessibility of residues in the EC2 of CXCR2 in the inactive state. Most of the 
residues in the EC2 were found to be solvent accessible in the inactive state, 
suggesting the residues might be involved in ligand recognition.  
Second, we studied the role of charged residues in the EC2 of CXCR2 in 
ligand binding and receptor activation using constitutively active mutants (CAM) 
of CXCR2, D9K and D9R. Combinatorial mutations consisting of the CAM in the 
amino terminus and single mutations of charged residues in the EC2 were 
generated to study two concepts including “attraction” and “repulsion” models. 
The mutant receptors were used to test their effects on cell surface expression, 
ligand binding, receptor activation through PLC-β3, and cellular transformation. 
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All the mutations in the repulsion model result in CXCR2 receptors that are 
unable to bind ligand, suggesting that each of the Arg residues in the EC2 are 
important for ligand recognition. Interestingly, mutations in the attraction model 
partially inhibited receptor activation by the CAM D9K, suggesting that Glu198 
and Asp199 residues in the EC2 are associated with receptor activation. 
Furthermore, a novel CAM, E198A/D199A, was identified in this study. These 
negatively charged residues are very close to a conserved disulfide bond linking 
the EC2 and the third transmembrane.  
In this sense, these current discoveries concerning the structural basis of 
CXCR2 and interdisciplinary approaches would provide new insights to 
investigate unknown mechanisms of interaction with its cognate ligands and 
receptor activation. 
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PART I  
GENERAL INTRODUCTION 
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Chapter 1 G protein-coupled receptors 
 
An overview 
G protein-coupled receptors (GPCRs) are the largest family of membrane-
bound receptors found in eukaryotes including yeast and mammals. There are 
1,000 genes in the human genome that encode GPCRs and comprise diverse 
groups of receptors for ligands such as hormones, neurotransmitters, 
chemokines, and calcium ions.  GPCRs can be sensory receptors for various 
odorants, bitter and sweet taste, and photons of light (1, 2). Furthermore, GPCRs 
regulate a variety of biological pathways inside cells and are an ideal target for 
the development of effective drugs to treat human conditons/disorders (Table 1) 
(3). 
The main structural feature of GPCRs is the conservation of three 
intracellular and extracellular loops connecting seven transmembrane domains. 
Localization of GPCRs on the cell surface allows for the transfer of extracellular 
stimuli into intracellular biochemical responses. Upon ligand binding, GPCRs 
undergo conformational changes to activate intracellular signaling cascades (4). 
The change initiates the activation of heterotrimeric G proteins. This protein 
complex includes G alpha (Gα), G beta (Gβ), and G gamma (Gγ) subunits and 
upon activation leads to the release of guanosine diphosphate (GDP) and the 
concomitant binding of guanosine triphosphate (GTP).  Upon exchange, the Gα 
protein disassembles from the Gβγ dimer. The released G protein can regulate 
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the stimulation or inhibition of secondary messenger molecules including 
adenylate cyclase, guanylyl cyclase, phospholipases, or ion channels. 
Phosphorylation of the cytoplasmic domains of GPCRs by GPCR kinases and 
arrestins are involved in receptor desensitization and internalization (5, 6).  
Resolution of GPCR structures has been solved in the past few years. 
Although there are many limitations to structural resolution such as heterologous 
expression systems, purification of GPCRs, and their large molecular size, five 
crystal structures of GPCRs have been successfully elucidated including bovine 
rhodopsin, human β2 adrenergic (β2AR), avian β1AR, human A2A adenosine 
receptor, opsin, and human CXC chemokine receptor 4 (CXCR4) (7, 8). 
Furthermore, structural information derived from mutagenesis, biochemical, 
biophysical, and computational modeling approaches have added to our 
understanding of the conformational changes in GPCRs (2, 9-11). These studies 
have provided new insights into GPCR structure and activation. 
 
Classification of GPCRs 
All GPCRs share the same structural basis of seven transmembranes 
connected via three extracellular and intracellular loops, an amino terminus, and 
carboxy terminus. However, few sequences are conserved among the different 
GPCRs, which are commonly classified into six families (http://gpcr.org/).  
The families of class A, B, and C are grouped on the basis of sequence 
similarity (2). Class A is the largest family of GPCRs and is considered 
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rhodopsin-like receptors. This family comprises receptors for various ligands 
including peptides and small molecules (12). Distinct regions were identified as 
highly conserved residues such as the (D/E)R(Y/W) motif at the bottom of 
transmembrane (TM) 3 and the NPXXY motif in TM7 that play critical roles in 
receptor structure and function (13-15). Class B, also called secretin-like 
receptors, is composed of the receptors for gastrointestinal peptide hormone 
family, corticotropin-releasing hormone, calcitonin and parathyroid hormone (2). 
In this class of receptors, the amino terminus and extracellular loops are highly 
associated with ligand binding, whereas there is no evidence for the involvement 
of transmembrane helices. However this is not based on the crystal structure as 
no class B receptor structures have been solved to date (16). This family of 
receptors is characterized by forming tight network structures of disulfide bonds 
with several cysteine residues localized on the amino terminus. Class C is known 
as metabotropic glutamate receptors. Their very large amino terminus (300-600 
amino acids) is involved in ligand recognition. Two distinct lobes of the amino 
terminus of these receptors are used to bind ligand in a “Venus flytrap” manner 
(1, 17). Class D and E are minor families containing STE2 and STE3 yeast 
pheromone receptors, respectively. Class F is composed of cyclic adenosine 
monophosphate (cAMP) and archaebacterial opsin receptors. 
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Table 1. GPCR as drug targets. 
Receptor Drugs and some key indications 
AT1 angiotensin II 
receptor 
Antagonists (e.g. losartan) in the treatment of essential hypertension or congestive heart 
failure  
α1A-adrenergic receptor
  
Antagonists (e.g. tamsulosin) to treat micturition (bladder emptying) disorders associated 
with enlarged prostate glands  
β1-adrenergic receptor
  
Antagonists (e.g. propranolol, atenolol, metoprolol, carvedilol) to treat essential 
hypertension or congestive heart failure  
β2-adrenergic receptor
  
Agonists (e.g. terbutaline, salbutamol, formoterol, salmeterol) for treatment of 
obstructive airway disease or premature labor  
D2 dopamine receptor
  
Antagonists (e.g. haloperidol and clozapine) to treat schizophrenia  
Agonists (e.g. levodopa) for the treatment of Parkinson’s disease 
D3 dopamine receptor
  
Antagonists (e.g. haloperidol) in the treatment of schizophrenia  
5-HT2A receptor  Antagonists (e.g. clozapine) to treat schizophrenia  
Indirect agonists (e.g. fluvoxamine) for the treatment of depression 
5-HT2C receptor  Antagonists (e.g. clozapine) to treat schizophrenia  
Table modified from Insel et al. (3)) 
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Tertiary structure of GPCRs 
Studies focusing on the structure of GPCRs are very important to 
understand their function and for drug development against GPCR mutants that 
cause disease (7, 18). During the past several years, remarkable progress has 
been made in the structural biology of GPCRs. This is due to specialized 
methods to resolve their protein structures including X-ray crystallography, 
electron microscopy or diffraction, nuclear magnetic resonance (NMR) 
spectroscopy, and molecular modeling (14, 19-21). Currently, Six GPCRs in the 
inactive state (in the absence of ligand) have been crystallized including human 
β2 adrenergic receptor (β2AR), avian β1AR, human A2A adenosine receptor, CXC 
chemokine receptor 4 (CXCR4), as well as bovine rhodopsin and opsin (8, 13, 
22-26). The high-resolution structural analysis has provided the molecular basis 
to address the structure and function of GPCRs (7) (Fig. 1). In order to obtain 
stability and conformational homogeneity for GPCR crystallization, various 
modifications have been tried with antibodies, fusion proteins, agonists, 
stabilizing mutants, and special crystallization environments. 
The first GPCR crystallized was bovine rhodopsin, composed of the 
protein opsin and 11-cis-retinal (13). Fifteen bovine rhopdosins (or opsins) have 
now been crystallized and published (14). There are significant structural 
differences in the third intracellular loop (IC3) between the crystal structures, 
suggesting that this part is important for movement in order for transducin (or Gαq 
for squid rhodopsin) to couple to the receptor. Although there is the conservation 
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of common structural features of the GPCRs, bovine rhodopsin has irregular 
transmembrane helices, especially with respect to bending at Pro residues and 
kinking around Gly-Gly residues (13, 27). The presence of Pro267, a highly 
conserved residue in TM6, causes a significant distortion suggesting that the 
proline may function as a toggle switch to transfer motions from the extracellular 
surface to the cytoplasmic surface (28). The proline in other GPCRs like β2AR 
may also be a crucial residue for receptor function. Rhodopsin and β2AR have a 
conserved Pro in TM6 that is important for receptor activation (29, 30). Two 
adjacent Gly residues (Gly89 and Gly90 of rhodopsin) that are conserved in 
many GPCRs induce a π-helix (i+5i hydrogen bonding) in TM2 (31, 32). The 
amino terminus and three extracellular loops are moved towards each other to 
make a compact structure forming the chromophore-binding pocket (22, 33). In 
the amino terminus of rhodopsin, post-translational modifications were found on 
several distinct residues including glycosylations of Asn2 and Asn15 and 
acetylation of Met1 (34, 35). Thus, pairs of β-sheets almost parallel to the 
membrane are localized on the amino terminus. 
The crystal structures of class A GPCRs show a highly conserved 
disulfide bond linking the Cys residue on the second extracellular loop (EC2) 
between TM4 and TM5 and a Cys on the front region of TM3. Rhodopsin has two 
short β-sheets associated with the ligand-binding pocket on its EC2 (13). The 
EC2 of rhodopsin, but not EC1 and EC3, is folded deeply into the helix bundles, 
whereas the EC2 of β2AR and β1AR are exposed to the solvent and contain a 
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short α-helix structure tied by intra- and inter-disulfide bonds to create a cavity for 
ligand binding (22, 24). The EC2 is crucial for the formation of the ligand binding 
pocket has also been observed in other class B GPCRs including complement 
factor 5a receptor (C5aR) as well as other class A GPCRs (36, 37).  
One of highly conserved motifs, (D/E)R(Y/W), is positioned in the second 
intracellular loop (IC2) of all the crystal structures. The tripeptide motif on the 
boundary of TM3 forms an ‘ionic lock’ with Glu on TM6 and has been shown that 
this linkage is crucial for maintaining the receptors in an inactive state (38). The 
ionic lock was observed on the crystal structure of rhodopsin, but not β2AR and 
β1AR. However, the fact that mutation of the ionic lock in β2AR increases 
constitutive activity supports the formation of the linkage in the receptor (39). 
Disruption of the ionic lock in β2AR is accomplished by the contact of the Arg (R) 
residue of the (D/E)R(Y/W) motif and T4 lysozyme fused to IC3 (22, 40). On the 
other hand, it is unclear why an inverse agonist bound to β1AR showed disruption 
of the linkage (24). Interestingly, in rhodopsin, the tripeptide Val137-Val138-
Val139 is located next to the highly conserved (D/E)R(Y/W) motif and might keep 
rhodopsin in the inactive state (33).  
The crystal structures of rhodopsin and β2AR have been used to create 
homology models for other GPCRs that have not been solved (32, 41, 42). These 
model predictions are based on the fact that GPCRs have highly conserved 
motifs and structural conservation, even though their primary sequences are 
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quite divergent (43). One study compared all the transmembrane proteins of the 
different GPCRs to one another (14).  
  10 
 
Figure 1. Comparison of GPCR structures.  
Bovine rhodopsin (purple), avian β1AR (orange) and human A2A adenosine 
receptor (green) are each superimposed on the human β2AR structure (blue). 
The extracellular loop2 (EC2), intracellular loop (IC2), cytoplasmic helix 8 (H8) 
and transmembrane (TM) segments are labeled on one of the structures. Figure 
from Rosenbaum et al (7). 
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This study showed that all the rhodopsin structures superposed well, except for 
squid rhodopsin.  Interestingly, the β2AR and β1AR superpose poorly on each 
other, whereas they fit quite well with rhodopsin. Additional studies using 
homology modeling suggests which crystallized GPCR is a better template for 
predicting the structures of the other uncrystallized GPCRs (44). This study 
showed that current crystal structures of GPCRs are not sufficient for homology 
modeling and drug design, because only 3 subfamilies including rhodopsin, 
adenosine, and adrenergic receptor have crystal structures. However, it was 
suggested that multiple-template homology modeling using all crystallized GPCR 
structures could improve the current templates for dynamic simulations like 
ligand docking.  
Recently the crystal structure of a chemokine receptor that belongs to 
class A GPCRs family was resolved (8) (Fig. 2). The CXCR4 structure provides 
new insights into its interaction with ligand, CXCL12, but also with human 
immunodeficiency virus (HIV) glycoprotein gp120. Furthermore, this new 
structures will aid in modeling the structure and function of other chemokine 
receptors, even though each has distinct characteristics in its interaction with 
their cognate ligands. 
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Figure 2. Crystal structure of the chemokine receptor CXCR4 and its 
structural similarity with other crystal GPCRs.  
Overall fold of the CXCR4-IT1t complex and comparison with other GPCR 
structures. (A) Overall fold of the CXCR4-2–IT1t. The receptor is colored blue. 
The amino terminus, first extracellular loop (EC1), EC2, and EC3 are highlighted 
in brown, blue, green, and red, respectively. The compound IT1t is shown in a 
magenta stick representation. The disulfide bonds are yellow. Conserved water 
molecules are shown as red spheres. (B) Comparison of transmembrane helices 
for CXCR4 (blue); β2AR (PDB ID: 2RH1; yellow); A2AAR (PDB ID: 3EML; green); 
and rhodopsin (PDB ID: 1U19; pink). Figure from Wu et al (8). 
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Ligand binding and receptor activation 
Numerous studies of GPCRs aim to understanding the mechanism of 
ligand binding and receptor activation using biological, biochemical, and 
biophysical approaches (45). Various methods were used to identify the binding 
domains including site-directed and random mutagenesis, receptor chimeras, 
competition with synthesized peptides, and addition of probes. For 
bioinformatical approaches, this experimental data was applied to improve 
ligand-docking model (46).  
Despite the variation in the mechanism of ligand binding, there are some 
similarities between the interaction of ligands and receptors. Small ligands 
(photon, biogenic amines and nucleosides) bind within transmembrane regions, 
whereas large molecules like peptides and proteins bind to extracellular loops 
(45). Peptide ligands show direct interaction of both amino-terminus and 
extracellular loops (4). However, some peptide ligands can interact with 
transmembrane domains as well as extracellular loops (47). 
Initially, a simple model was used to explain how agonist binding induces 
a conformational change. The model was called the “two-state model” with an 
equilibrium between the inactive conformation (R) and active conformation (R*) 
(48). However, more recently crystal structures and biophysical studies led to the 
creation of new model known as the “multi-state” model (7, 49). Upon ligand 
binding, GPCRs become activated and undergo a conformational change, 
resulting in G protein activation. The conformational changes leads to the 
  14 
rearrangement of the interhelical interactions on transmembranes including TM3, 
TM6 and TM7. The extracellular domains and the flexible third intracellular loop 
are involved in this rearrangement. The recognition sites such as the second 
intracellular loop (IC2) including (D/E)R(Y/W) motif close to TM3 are exposed to 
activate signaling partners including heterotrimeric G proteins and arrestins (50, 
51) (Fig. 3). A highly conserved Pro residue on TM6 allows the rigid 
transmembrane helices to move as part of the conformational change (29). 
Post-translational modifications on cytoplasmic domains of GPCRs are 
involved in receptor desensitization and internalization (5, 6). GPCR kinases and 
arrestins are involved in these modifications. In the cases of rhodopsin and β2AR, 
there are residues for different post-translational modifications on their 
cytoplasmic loops, including palmitoylation at Cys, phosphorylation at Ser, and 
ubiquitinylation at Lys (35, 52).  
Signal transduction of GPCRs 
The cytoplasmic domains of GPCRs interact with proteins that are 
responsible for initiating intracellular signaling cascades (53) (Fig. 4). 
Heterotrimeric G proteins are predominantly used as the first intracellular 
modulators of GPCR signaling (54). To date, 23 Gα protein subtypes have been 
identified and are classified into 4 different groups such as Gαi/o, Gαs, Gαq/11, and 
Gα12/13. There are also 6 Gβ and 11 Gγ proteins (55). 
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Figure 3. Molecular model of the M3 muscarinic acetylcholine receptor 
(M3R)-Gαq complex. 
(a) Side view of the complex between the inactive state of the M3R and the Gq 
heterotrimer. The M3R is shown in red, Gαq in yellow, Gβ in gray and Gγ in pink. 
(b) Enlargement of the M3R-Gαq interface. M3R residues are shown in blue, Gαq 
residues in orange. The interaction between R31C in the αN helix of Gαq and 
l173C in the i2 loop of the M3R provided a key contact site for the docking 
process. The C terminus of Gαq points toward the intracellular core of the 
receptor, between the IC2 and helix 8 (H8). The finding that the C-terminal 
residues of Gαq can interact with multiple M3R residues in the IC2 loop (leu173 
and Arg176) and the N-terminal portion of H8 (Thr549, Thr552 and Thr556) 
suggests that the extreme C terminus of Gαq is conformationally highly flexible. 
Agonist-induced M3R activation promotes the formation of cross-links between 
the extreme C terminus of Gαq and the cytoplasmic end of TM6 (A488C) (gray 
arrow) and the N-terminal segment of H8 (T549C and T552C) of the M3R. 
Moreover, in the activated state of the receptor, a residue in the α4-β6 loop of 
Gαq (D321C) could be cross-linked to the N-terminal portion of H8 (K548C, 
T549C and T552C) (gray arrow). Figure from Hu et al (51). 
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The expression pattern and combination of the heterotrimeric G proteins is cell 
type-dependent, indicating that GPCRs can interact with certain G proteins that 
are available in a given cell or localize closely to the receptors. Although it has 
been shown that second intracellular loop (IC2), IC3, and cytoplasmic terminus 
function as key regions for interaction with G protein coupling, no consensus 
motif has been identified (56). 
Activation of the three G proteins leads to exchange of guanosine 
diphosphate (GDP) and guanosine triphosphate (GTP), followed by dissociation 
of Gα protein and Gβγ dimer. The released G proteins can regulate the 
stimulation or inhibition of secondary messenger molecules including adenylate 
cyclase, guanylyl cyclase, phospholipases, or ion channels.  
Each family of G proteins has distinct characteristics (2). The Gαs family 
functions as a stimulator of adenylyl cyclase to increase cyclic adenosine 
monophosphate (cAMP) levels. Whereas, Gαi/o proteins play a role in the 
inactivation of adenylyl cyclase, resulting in a decrease of cAMP levels. 
Furthermore, almost all the proteins that belong to Gαi/o family are pertussis 
toxin-sensitive (PTX). Gαq/11 including Gα14, Gα15, and Gα16 can bind 
phospholipases C-β (PLC-β) (57). Proteins of the Gα12/13 family are ubituitously 
expressed and localized (58). This family can activate small G proteins (Rho and 
Ras family), Src family tyrosine kinase, and phospholipase D (PLD). Interestingly, 
when Gα12/13 mutants are in a constitutively active form, cellular transformation is 
induced in a Rho signaling-dependent manner (59). Gβ and Gγ proteins have 
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been shown to function as a heterodimer. This complex induces adenylyl cyclase, 
PLC-β, and phosphoinositide-3 kinase (PI3K) (60, 61).  
Agonist-occupied GPCRs induce not only signal transduction cascades 
but also activation of various intracellular regulatory molecules. The G protein-
coupled receptor kinases (GRKs) are serine/threonine kinases. GRKs catalyze 
phosphorylation of GPCRs and recruit arrestins to the phosphorylated GPCR for 
receptor desensitization and internalization (62, 63). After activation, the 
regulators of G protein signaling (RGS) proteins are used to return the GTP-
bound Gα proteins to their basal state (Gα) via GTP hydrolysis. This results in 
the reassociation of the heterotrimeric G proteins and inactivation of the GPCR 
(64). Interestingly, arrestins function not only in GPCR desensitization and 
internalization but also as a G protein-independent signal transducer (65, 66). 
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Figure 4. Diversity of G-protein-coupled receptor signaling.  
Various ligands use GPCRs to stimulate membrane, cytoplasmic and nuclear targets. 
GPCRs interact with heterotrimeric G proteins composed of α, β and γ subunits that are 
GDP bound in the resting state. Agonist binding triggers a conformational change in the 
receptor, which catalyses the dissociation of GDP from the α subunit followed by GTP-
binding to Gα and the dissociation of Gα from Gβγ subunits. The α subunits of G 
proteins are divided into four subfamilies: Gαs, Gαi, Gαq and Gα12, and a single GPCR 
can couple to either one or more families of Gα proteins. Each G protein activates 
several downstream effectors. Typically Gαs stimulates adenylyl cyclase and increases 
levels of cyclic AMP (cAMP), whereas Gαi inhibits adenylyl cyclase and lowers cAMP 
levels, and members of the Gαq family bind to and activate phospholipase C (PLC), 
which cleaves phosphatidylinositol bisphosphate (PIP2) into diacylglycerol and inositol 
triphosphate (IP3). The Gβ subunits and Gγ subunits function as a dimer to activate 
many signaling molecules, including phospholipases, ion channels and lipid kinases. 
Besides the regulation of these classical second-messenger generating systems, Gβγ 
subunits and Gα subunits such as Gα12 and Gαq can also control the activity of key 
intracellular signal-transducing molecules, including small GTP-binding proteins of the 
Ras and Rho families and members of the mitogen-activated protein kinase (MAPK) 
family of serine-threonine kinases, including extracellular signal-regulated kinase (ERK), 
c-jun N-terminal kinase (JNK), p38 and ERK5, through an intricate network of signaling 
events that has yet to be fully elucidated. Ultimately, the integration of the functional 
activity of the G-protein-regulated signaling networks controls many cellular functions 
and the aberrant activity of G proteins and their downstream target molecules can 
contribute to cancer progression and metastasis. 5-HT, 5-hydroxytryptamine; ECM, 
extracellular matrix; GABA, gamma-aminobutyric acid; GEF, guanine nucleotide 
exchange factor; GRK, G protein receptor kinase; LPA, lysophosphatidic acid; PI3K, 
phophatidylinositol 3- kninase; PKA and PKC, protein kinase A and C; S1P sphingosine-
1-phosphate. Figure from Dorsam and Gutkind (53). 
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Chapter 2 CXC Chemokine Receptor 2 (CXCR2) and 
Cognate Chemokines 
 
Chemokines and cognate chemokine receptors 
Chemokines are a family of small cytokines, or cell-signaling molecules, 
that regulate inflammation through GPCRs expressed on leukocytes (67). In 
higher vertebrates, over 50 different chemokines have been identified (68). 
These proteins induce various biological and biochemical activities such as cell 
migration, cell adhesion, and exocytosis (69). There are four families of 
chemokines including C, CC, CXC, and CX3C. The chemokines of C or CC 
subfamily have a single Cys residue or two contiguous Cys residues on the 
amino terminus of the protein, respectively. CXC or CX3C subfamilies contain 
one or three amino acids between the two cysteine residues. The CXC 
chemokines are classified into two subfamilies: the glutamate-leucine-arginine 
(ELR) and non-ELR families. Generally, the ELR CXC chemokines promote 
angiogenesis while the CXC chemokines that lack the ELR motif inhibit 
angiogenesis (70). However, the non-ELR chemokine CXCL12 (SDF-1) induces 
angiogenesis, which may relate to its ability to induce cancer metastasis (71).  
In the early 1990s, two CXC chemokine receptors for CXCL8 (IL-8) were 
the first identified chemokine receptors. Now there are 19 chemokines receptors 
including 7 members for CXC, 11 for CC, 1 for C and 1 for CX3C type (72-76).  
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Table 2. Chemokine receptor and their cognate chemokine families in 
humans 
Receptor Swissprot Ligand(s) Main function 
CXC chemokine receptors 
CXCR1 P25024 CXCL1 (Groα), CXCL6 (GCP-2), 
CXCL8 (IL-8) 
Neutrophil migration; innate immunity; acute 
inflammation 
CXCR2 P25025 CXCL1 (Groα), CXCL2 (Groβ), CXCL3 
(Groγ), CXCL5 (ENA-78), CXCL6 
(GCP-2), CXCL7 (NAP-2), CXCL8 (IL-
8) 
Neutrophil migration; innate immunity; acute 
inflammation; angiogenesis  
CXCR3 P49682 CXCL9 (Mig), CXCL10 (IP-10), 
CXCL11 (I-TAC) 
T cell migration; adaptive immunity; Th1 
inflammation  
CXCR4 P30991 CXCL12 (SDF-1 α/β) B cell lymphopoiesis; bone marrow 
myelopoiesis; central nervous system and 
vascular development; HIV infection  
CXCR5 P32302 CXCL13 (BLC, BCA-1) B cell trafficking; lymphoid development  
CXCR6 O00574 CXCL16 T cell migration  
CXCR7 P25106 CXCL11 (I-TAC), CXCL12 (SDF-1 α/β) Dendritic and B cells; HIV infection 
CC chemokine receptors 
CCR1 P32246 CCL3 (MIP-1α, LD78α), CCL5 
(RANTES), CCL7 (MCP-3), CCL8 
(MCP-2), CCL13 (MCP-4), CCL14 
(HCC-1), CCL15 (HCC-2), CCL16 
(HCC-4), CCL23 (MPIF-1) 
T cell and monocyte migration; innate and 
adaptive immunity; inflammation 
CCR2 P41597 CCL2 (MCP-1), CCL7 (MCP-3), CCL8 
(MCP-2), CCL13 (MCP-4), CCL16 
(HCC-4), 
T cell and monocyte migration; innate and 
adaptive immunity; Th1 inflammation 
CCR3 P51677 CCL5 (RANTES), CCL7 (MCP-3), 
CCL8 (MCP-2), CCL11 (Eotaxin), 
CCL13 (MCP-4), CCL15 (HCC-2), 
CCL24 (Eotaxin 2), CCL26 (Eotaxin 3), 
CCL28 (MEC) 
Eosinophil, basophil, and T cell  
migration; allergic inflammation 
CCR4 P51679 CCL17 (TARC), CCL22 (MDC),  T cell and monocyte migration; allergic 
inflammation  
CCR5 P51681 CCL3 (MIP-1α, LD78α), CCL4 (MIP-
1β), CCL5 (RANTES), CCL8 (MCP-2), 
CCL16 (HCC-4) 
T cell and monocyte migration; innate and 
adaptive immunity; HIV infection  
CCR6 P51684 CCL20 (MIP3α) Dendritic cell migration  
CCR7 P32248 CCL19 (MIP3β), CCL21 (SLC),  T cell and dendritic cell migration; lymphoid 
development; primary immune response 
CCR8 P51685 CCL1 (I-309) T cell trafficking  
 
CCR9 P51686 CCL25 (TECK) T cell homing to gut  
CCR10 P46092 CCL27 (CTACK, ILC), CCL28 (MEC) T cell homing to skin 
CCR11 Q9NPB9 CCL19 (MIP3β), CCL21 (SLC), CCL25 
(TECK) 
Expressed abundantly in the heart 
CX3C chemokine receptor 
CX3CR1 P49238 CX3CL1 (Fractalkine) 3T cell and NK cell trafficking and adhesion; 
innate and adaptive immunity; Th1 
inflammation 
C chemokine receptor 
XCR1 P46094 XCL1 (Lymphotactin, SCM-1α) T cell trafficking  
Table modified from Murphy et al. (74), chemokine/chemokine receptor 
nomenclature (75), and Zlotnik et al (76). 
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The binding of chemokine ligands to their receptors is very promiscuous except 
for that of CXCL12 (SDF-1) and CXCR4. 
Interaction of CXCR2 and its cognate chemokines  
Most chemokine receptors can be activated by more than one chemokine 
(77). CXC chemokine receptor 2 (CXCR2) binds multiple CXC chemokines 
including CXCL1 (Growth related oncogene-α (GRO-α)), CXCL2 (GRO-β), 
CXCL3 (GRO-γ), CXCL5 (epithelial neutrophil-activating protein 78 (ENA78)), 
CXCL6 (granulocyte chemotactic protein 2 (GCP2)), CXCL7 (neutrophil-
activating peptide 2 (NAP2)), and CXCL8 (78, 79). Although CXCR1 and CXCR2 
show over 75% amino acid identity, only CXCL6 and CXCL8 activate CXCR1, 
suggesting that the two chemokine receptors have different mechanisms for 
chemokine ligand binding (80). There are three divergent regions between the 
two receptors including the amino terminus, EC2, and cytoplasmic terminus, 
however studies for ligand binding has been focused on the amino terminus and 
EC2 (81, 82). Studies using chimeric CXCR1/2 receptors showed that CXCL1, 
CXCL7, and CXCL8 bind to overlapping but distinct regions of CXCR2 (83, 84). 
The amino terminus and EC2 of CXCR2 are critical regions for binding CXCL1 
and CXCL7, whereas only EC2 is involved in CXCL8 ligand binding. However, 
use of synthetic peptides corresponding to the amino terminus and extracellular 
loops of CXCR2, the amino terminus, but not the EC2, was also identified as a 
binding motif for CXCL8 (85). Additionally, site-directed mutagenesis of the 
amino terminus and EC1 of CXCR2 showed that specific charged residues on 
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the amino terminus of CXCR2 are critical for CXCL1 (Asp9, Glu12, Lys108 and 
Lys120 of CXCR2) and CXCL8 (Glu7, Asp9 and Glu12 of CXCR2) binding (86). 
Site-directed mutagenesis and chimeric receptors of CXCR1/2 including the 
amino terminus, TM4, EC2, TM5, EC3, and TM7 showed that the amino terminus 
of CXCR1 and EC2 of CXCR2 are important for CXCL8 binding, while the amino 
terminus of CXCR2 is involved in CXCL1 binding (87). A recent study using a 
random phage-epitope library showed certain synthetic epitopes inhibited binding 
of CXCL8 (or antibody) to CXCR1/2 and blocked chemotaxis of human 
neutrophils (88). The consensus sequences of the synthetic epitopes were 
identical with residues on amino terminus of CXCR1/2 (Trp10-Asp11-Phe12 for 
CXCR1 and Asp13-Phe14-Trp15 for CXCR2), indicating that amino terminus of 
the receptors is important for ligand binding. Although some of the information 
about ligand binding is not consistent, the amino terminus and/or the EC2 are 
critical for binding to its cognate chemokines. Additionally, amino acid 
substitutions showed that the Cys residues of CXCR2 are highly associated with 
CXCL8 ligand binding, but not surface expression, including Cys119, Cys196, 
and Cys286 in the extracellular loops and Cys308 in TM7 (89).  
The amino terminus of CXCL8 is important for high affinity and binding 
specificity (90). Site-directed mutagenesis of CXCL8, two binding sites for 
CXCR1 and CXCR2 were predicted (91). In the study, two residues, Tyr13 and 
Lys15, in the amino terminus of CXCL8 were identified as important sites for 
CXCR1 binding. Both Glu4-Leu5-Arg6 (ELR) motif and Tyr13-Ser14-Lys15 are 
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exposed to the surface and localize on opposite ends on the same face of the 
ligand. The fact that the distance between the two regions is 23 angstroms (2.3 
nm) suggests that the two sites of CXCL8 can span the distance between the 
amino terminus and third extracellular loop of CXCR1/2. Additionally, 
substitutions of residues of bovine CXCL8 were used to identify analogues with 
high affinity (K11R) or antagonist activity (K11R/G31P) (92, 93). The 
human/bovine chimeric hbG31P (bovine CXCL8(3-44)K11R/G31P-hCXCL8(45-
72)) preserved antagonist activity, indicating that the analogue can be used as 
potential antagonist for human CXCL8 and its receptors (94).  
CXCR2 normally expressed on neutrophils contains two N-glycosylation 
sites (95). There are three possible residues for N-glycosylation at Asn17, 
Asn186, and Asn197. Because of the proximity of the Asn residues and 
transmembranes, Asn17 and Asn197 are probably the most likely candidates for 
glycosylation. Asn186 is closer to the transmembrane domain and probably 
cannot handle the N-linked sugar moieties. N-glycosylation on the extracellular 
domains of CXCR2 is not involved in ligand binding but contributes to the 
maintenance of the receptors expressed on the cell surface (73, 84, 95). 
 
Receptor activation and signal transduction of CXCR2 
CXCR2 is expressed on a various tumor cells including breast cancer, 
head and neck cancer, melanoma, pancreatic, and ovarian cancer (96-100). 
CXCL8 can activate both CXCR1 and CXCR2 receptors and has been 
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characterized as a mediator of cancer progression. Activation of these receptors 
promote the expression of genes highly associated with cell survival, proliferation, 
angiogenesis, and invasion (78, 101) (Fig. 5).  
Antagonists have been used to understand the mechanism of CXCR1 and 
CXCR2 activation. Competition binding with CXCL1 and CXCL8 and a small 
molecule antagonist, SB225002, to CXCR2 mutants was used to show how 
these chemokines activate the receptor (87). The antagonist binds to the 
transmembrane helices within CXCR2, but not to the ligand binding sites, and 
causes an allosteric change that blocks to binding of CXCL1 and CXCL8. 
Currently, two different antagonists were used to understand the difference 
between CXCR1 and CXCR2 in antagonism (102). It has been shown that the 
EC2 of the receptors does not play a crucial role in compound antagonism, and a 
single amino acid (Lys320 for CXCR2 and Asn311 for CXCR1) of the receptor is 
important to allosteric binding. 
Viral oncogene ORF74 encoded by Kaposi’s sarcoma-associated 
herpesvirus (human herpesvirus 8), also called KSHV-GPCR, is the closest  
homologue to CXCR2 (103). KSHV-GPCR constitutively activates AP-1, CREB, 
NFAT, and MAPK via Gαi or Gαq, and NF-κB through only Gαq. This is true in 
different cell lines including COS-7, primary effusion lymphoma (PEL), and 
endothelial cells (104-107). Currently, studies of M33 from murine 
cytomegalovirus (MCMV) and US28 of human cytomegalovirus (HCMV), both 
viral GPCR homologues,  
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Figure 5. Characterized IL-8 signaling pathways.  
A schematic diagram illustrating the range of signaling pathways that are activated after 
stimulation of CXCR1 and/or CXCR2 receptors with IL-8. After activation of 
heterotrimeric small G proteins, IL-8 signaling promotes activation of the primary 
effectors phosphatidyl-inositol-3-kinase or phospholipase C, promoting the activation of 
Akt, PKC, calcium mobilization and/or MAPK signaling cascades. These signaling 
pathways have been shown to promote protein translation (left) and regulate the activity 
of a range of transcription factors (bottom). Solid gold lines, transcription factors whose 
activity has been shown to be positively regulated by IL-8 signaling using various 
reporter assays. In the case of signal transducers and activators of transcription 3 
(STAT3) and h-catenin, IL-8 signaling has been shown to promote nuclear translocation 
of these factors; however, transcriptional activation of either factor remains to be shown. 
Dashed lines, the putative pathways through which IL-8 signaling regulates transcription 
factor activity. In addition, IL-8 signaling activates members of the RhoGTPase family 
and activates a number of nonreceptor tyrosine kinases (e.g., Src family kinases and 
FAK) that regulate the architecture of the cell cytoskeleton and its interaction with the 
surrounding extracellular environment. Figure from Waugh and Wilson (101). 
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have been shown to activate the Gαq protein and induce phopholipase C-β (PLC-
β) activity, followed by stimulation of CREB and NF-κB signals (108-111). 
Additionally, M33 can induce CREB and NF-κB stimulation via a PLC-β 
independent manner (112). On the other hand, another GPCR homolog, UL33, of 
HCMV enhances CREB transcriptional activities by the Gs pathway not the Gq/11 
pathway (113). 
It has been shown that CXCR2 can couple to different G proteins in 
different cell lines, including Gαi, Gα12, Gα13, Gα14, Gα15, Gα16, and Gβγ subunits 
(114-116). CXCR2 can interact with non-G proteins like vasodilator-stimulated 
phosphoprotein (VASP) to activate downstream signaling (117). It is suggested 
that multiple signaling cascades can be activated in a G-protein-dependent and -
independent manner.  
A point mutation of Asp143 (to Val, the same as KSHV-GPCR) of the 
highly conserved (D/E)R(Y/W) motif in CXCR2 leads to constitutive activation of 
the receptor and cellular transformation similar to KSHV-GPCR (118). 
Transformation was totally inhibited using AG490, a specific kinase inhibitor for 
JAK2-STAT3 signaling (119). Constitutive activation of KSHV-GPCR and CXCR2 
mutant D143V is highly associated with STAT3 phosphorylation. Another motif 
related to CXCR2 activation was identified in the cytoplasmic terminus (120). 
Mutation of the LLKIL motif inhibited chemotaxis via disruption of Akt, Rac1, and 
Cdc42 recruitment. Interestingly, EC2 as well as the carboxy terminus of CXCR2 
is important for activation and regulation of the receptor (84). Mutation of Asp199 
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(to Val) on EC2 delayed internalization of the receptor, whereas Asp199 
substitution with Asn restored internalization. Homology modeling of CXCR2 
based on rhodopsin showed that Asp199 functions to stabilize the receptor 
conformation using hydrogen bonds between several residues on EC2 (Fig. 6). 
A current study of CXCR2 expressed on ovarian cancer cells reported that 
cancer growth is regulated by MAPK and NF-κB pathways (121). Additionally, it 
was shown that CXCL1 binding to CXCR2 but not CXCR1 induced 
transactivation of the epidermal growth factor receptor (EGFR) via the chemokine 
receptor, followed by proliferation of ovarian cancer cells (122). 
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Figure 6. Computational modeling of the EC2 of rhodopsin, CXCR2, CXCR1, 
and the receptor mutants BD199VA, BD199N, and AV190DB.  
Shown are receptor interactions involving Asp190 of rhodopsin (A) and its 
corresponding residues Asp199 of the EC2 of CXCR2 (B), Val190 of CXCR1 (C), 
Val199 of BD199VA (D), Asn199 of BD199N (E), and Asp190 of AV190DB (F). The 
protein secondary structural elements are displayed as follows: α-helix, white; β-
sheet, yellow; turn, cyan; and random coil, purple. The color coding of receptor 
residue atoms is as follows: green, carbon; red, orange; and blue, nitrogen. H-
bond-forming residues (in stick depiction) in association with Asp190 in 
rhodopsin (Tyr192, Thr193, and Arg177) (A), Asp199 in CXCR2 (Thr186, Arg208, 
and Arg185) (B), Asn199 in BD199N (Thr186 and Arg185) (E), and Asp190 in 
AV190DB (Arg199) (F) are shown by white dotted lines. No H-bond was formed in 
CXCR1 (C) and BD199VA (D). The residues within 3.0 Å of Val190 (CXCR1) or 
Val199 (BD199VA) are represented. Figure from Nasser et al (84).  
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Statement of research aims 
Most chemokine receptors can be activated by more than one chemokine 
(77). CXC chemokine receptor 2 (CXCR2) binds multiple CXC chemokines 
including CXCL1 (GRO-α), CXCL2 (GRO-β), CXCL3 (GRO-γ), CXCL5 (ENA78), 
CXCL6 (GCP2), CXCL7 (NAP2), and CXCL8 (78, 79). Although CXCR1 and 
CXCR2 show over 75% amino acid identity, only CXCL6 and CXCL8 activate 
CXCR1, suggesting that the two chemokine receptors have different 
mechanisms for ligand binding (80). In previous studies with multiple chimeric 
receptors, it was shown that CXCR1 and CXCR2 have distinct mechanisms of 
ligand binding and receptor activation (80, 81, 83-88). The studies suggested that 
divergent regions including the amino terminus and second extracellular loop 
between the receptors are crucial in construction of selectivity determinants for 
different cellular responses. However, the mechanism of ligand binding and 
receptor activation is still unknown.  
First, in our study, CXCR2 structure is predicted on the basis of crystal 
GPCR structures including rhodopsin, β2AR by homology modeling, and CXCR4. 
The topology of the EC2 region of CXCR2 in the inactive state is determined by 
using substituted cysteine accessibility method (SCAM). 
Second, we studied the role of charged residues in EC2 of CXCR2 in 
ligand binding and receptor activation. Two concepts, “attraction” and “repulsion” 
models, were designed to investigate the mechanism of CXCR2 activation (Fig. 
14). To end that, we constructed combinatorial mutation sets consisting of 
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constitutively active mutants (CAM) Asp9 in the amino terminus and substitutions 
in EC2. These mutant receptors were generated by site-directed mutagenesis 
and transfected into mouse fibroblast NIH3T3 cell lines. The NIH3T3 cells stably 
expressing wild-type CXCR2 and mutant receptors were used to investigate cell 
surface expression of the receptor, ligand-binding, and receptor activation 
through phospholipase C-β3 (PLC-β3). 
 
 
  33 
 
 
 
PART II  
PREDICTION OF THE TERTIARY STRUCTURE OF 
CXCR2 AND STUDY OF THE CONFORMATION OF THE 
SECOND EXTRACELLULAR LOOP OF THE RECEPTOR 
IN AN INACTIVE STATE 
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Chapter 1 Abstract 
 
The first objective of this investigation was to predict the structure of 
CXCR2 based on known structures of crystallized GPCRs. Bovine rhodopsin, 
human β2-adrenergic receptor, and human CXCR4 were used for homology 
modeling of CXCR2 structure. Highly conserved motifs ((D/E)R(Y/W), NPXXY, 
toggle switch, and disulfide bonds) found in sequence alignments of the template 
GPCRs were helpful to generate CXCR2 models. Using Cα RMSDs, structural 
alignments of the seven transmembrane domains showed the individual models 
tend to be similar to their templates. Based on the sequence alignments and 
RMSD values, the CXCR4-based model shows a very similar structure to 
CXCR2. The second extracellular loop of the homology modeled CXCR2 
provided two β-strands like CXCR4 and the prediction is very similar with results 
obtained from web-based prediction programs. Superimposition of the second 
extracellular loop of CXCR4 and CXCR4-based CXCR2, showed the second 
extracellular loop of CXCR2 is structurally very similar with that of CXCR4 with 
below 2.0 Å RMSD. 
Furthermore, we studied solvent accessibility of residues in the second 
extracellular loop of CXCR2, a key region for ligand binding and receptor 
activation, in the inactive state of the receptor. MTSEA-biotin accessibility of 
substituted cysteine residues in second extracellular loop was measured by 
immunostaining of FITC-streptavidin using flow cytometric analysis. The 
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normalization of the accessibility was determined by surface expression levels of 
the substituted cysteine mutant receptors. Most of residues in the second 
extracellular loop were found to be solvent accessible in the inactive state of 
CXCR2, indicating that the residues might be involved in ligand binding. Most of 
the charged residues in second extracellular loop also have solvent accessibility. 
However, five amino acids 204TANWR208 showed no solvent accessibility, 
pointing to possible interaction with the amino terminus or other extracellular 
loops. Our finding of ligand binding sites for CXCR2 also indicated that most of 
the residues in the second extracellular loop could form a ligand binding pocket 
to contact CXCL8. 
In this sense, these current discoveries about structural basis of CXCR2 
and interdisciplinary approaches would provide new insights to investigate 
unknown mechanisms of interaction with its cognate ligands and receptor 
activation. 
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Chapter 2 Introduction 
 
CXCR2, also called IL-8RB, was initially identified as a chemokine 
receptor expressed on neutrophils (123). CXCR2 is a member of the rhodopsin-
like subfamily (class A) of G protein-coupled receptors, and has the closest 
homology to CXCR1, with 77% amino acid identity (72, 73, 123). Multiple 
chemokines can bind CXCR2 including CXCL1 (Growth related oncogene-α 
(GRO-α)), CXCL2 (GRO-β), CXCL3 (GRO-γ), CXCL5 (epithelial neutrophil-
activating protein 78 (ENA78)), CXCL6 (granulocyte chemotactic protein 2 
(GCP2)), CXCL7 (neutrophil-activating peptide 2 (NAP2)), and CXCL8 (78, 79). 
The function of CXCR2 has been studied in a variety of immune cells such as 
neutrophils and macrophages, indicating that the receptor plays a critical role in 
immune response and inflammation (121). Furthermore, it has been shown that 
CXCR2 receptors are also expressed on various cancer cells including breast 
cancer, head and neck cancer, melanoma, pancreatic, and ovarian cancer (96-
100). 
In previous studies utilizing chimeric receptors, it has been shown that 
CXCR1 and CXCR2 have distinct mechanisms of ligand binding and receptor 
activation (80, 81, 83-88). The studies suggested that divergent regions including 
the amino terminus and second extracellular loop between the receptors are 
crucial in construction of selectivity determinants for different cellular responses. 
The CXCL8, a chemokine ligand that binds to both CXCR1 and CXCR2, has 
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been used to study which part of the ligand is important to bind the receptors (90, 
91). Both the Glu4-Leu5-Arg6 (ELR) motif and Tyr13-Ser14-Lys15 on the amino 
terminus of CXCL8 might initially interact with the amino terminus and third 
extracellular loop of the receptors. However, a current study suggested another 
model that the N-loop (His18 to Phe21) of CXCL8 binds the amino terminus of 
the cognate receptors and then the ELR motif of the ligand interacts with the 
second extracellular loop of the receptors (124). Although there are different 
possible mechanisms of the interaction of CXCL8 and its cognate receptors, the 
fact that extracellular parts of CXCR1 and CXCR2 are crucial for ligand binding 
and receptor activation has been conserved. 
Six GPCRs in the inactive state have been crystallized including human β2 
adrenergic receptor (β2AR), avian β1AR, human A2A adenosine receptor, CXC 
chemokine receptor 4 (CXCR4) as well as bovine rhodopsin and opsin (8, 13, 22-
26). The high-resolution structural analysis has provided a crucial molecular 
basis to address structure and function of GPCRs (7). Previously, the crystal 
structures of rhodopsin and β2AR have been used to predict structures of GPCRs 
that are not structurally solved (32, 41, 42). The prediction is based on the fact 
that GPCRs have highly conserved motifs and structural conservation, even 
though their primary sequences are quite divergent (43). However, the limited 
crystallized structures are not sufficient for homology modeling and drug design 
of structurally unknown GPCRs (44). Recently, a novel crystal structure of 
chemokine receptor CXCR4 has been solved belonging to class A GPCRs (8). 
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The CXCR4 structure is expected to be the best template to homology model 
other chemokine receptors including CXCR1 and CXCR2.  
In GPCRs, the second extracellular loops in particular show highly 
variable length and non-conserved amino acid sequences (43). The function of 
EC2 in different GPCRs has been shown to negatively regulate receptor 
activation. In C5aR and rhodopsin receptors, the EC2 region plays a critical role 
in stabilization of the inactive conformation of GPCRs (36, 37, 125). Another 
example has been observed in the melanocortin receptor with the fact that a 
short length of EC2 and the absence of a conserved disulfide bond allow the 
receptor to induce a high basal activity (126). However, in the M3 muscarinic 
acetylcholine receptor (M3R), it has been shown that multiple residues on EC2 
are important in stabilizing the active state of the receptor (127).  
In our study, a CXCR2 structure is predicted on the basis of crystal GPCR 
structures including rhodopsin, β2AR, and CXCR4 by using homology modeling. 
Furthermore, the accessibily of residues in the EC2 region of CXCR2 in the 
inactive state is determined by using substituted cysteine accessibility method 
(SCAM).  
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Chapter 3 Materials and Methods 
 
Cell line and medium 
Human embryonic kidney (HEK) 293 cells were cultured with Dulbecco’s 
modified eagle medium (DMEM) containing 10% newborn calf serum (NCS), 1X 
non-essential amino acids (NEAA), and 1X penicillin/streptomycin.  
 
Cysteine-scanning mutagenesis 
The CXCR2 gene cloned into pRc/CMV vector was used as a template for 
site-directed mutagenesis. Forward and reverse primers were manually designed 
for single cysteine substitution of all the residues (from Phe183 to Lue214) in the 
EC2 of CXCR2 (Table 3). PCR mutagenesis was performed with a modification 
of the QuickChange® method (Stratagene). 1X PCR mixture (50 µl) contains 
300-400 ng of template plasmid including wild-type CXCR2 gene, 0.5 U Taq 
polymerase (Takara, Japan), 1X Taq polymerase buffer, 2 µl deoxynucleotide 
mixture, 10 pmoles each primer, and nuclease-free H2O. Cycling conditions were 
a cycle of 98 °C for 3 min, 35 cycles of 98 °C for 30 sec, 55 °C for 30 sec, and 72 
°C for 10 min, and a cycle of 72 °C for 20 min. Dpn I digestion treatment was 
performed, followed by cleaning via a PCR purification kit. All mutations were 
conformed by sequencing analysis (Molecular biology resource facility, University 
of Tennessee, Knoxville). 
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Expression of the CXCR2 receptor in HEK293 cells 
Plasmid DNAs of wild-type CXCR2 and mutant receptors were transiently 
transfected into HEK293 cells. The transfections were performed with 
Lipofectamine 2000 reagent according to the manufacturer’s instructions. 4.0 x 
105 HEK293 cells were seeded in 60 mm dishes one day before transfection. 4 
µg of plasmid DNA and 4 µl of Lipofectamine 2000 were individually diluted into 
250 µl fresh DMEM, incubated for 5 min at room temperature, and mixed 
together followed by incubation for 30 min at room temperature. The mixtures 
and 1 ml fresh DMEM were added to each 60 mm dish and incubated for 4 hr at 
37 °C. The mixtures was substituted with new medium including 10% newborn 
calf serum (NCS), followed by cultivation for 48 hr at 37 °C. 
 
MTSEA-biotin labeling and flow cytometry analysis 
2-[(biotinoyl)amino]ethyl methanethiosulfonate (MTSEA-biotin) labeling 
was performed as previously described (9) with the following modifications. 
MTSEA-biotin was dissolved in dimethyl sulfoxide (DMSO) and prepared as a 20 
mM stock. A final concentration of 0.1 mM MTSEA-biotin in 1X PBS was used for 
MTSEA-labeling. Cells expressing the wild-type CXCR2 and mutant receptors 
were harvested by using cell scrapers (BD FalconTM, NJ) with 2 ml 1X PBS. After 
  41 
centrifugation, 200 µl MTSEA-biotin was added to the cells for 2 min at room 
temperature, followed by washing with 4ml 1X PBS. 
In order to determine cell surface expression of CXCR2, 25 µl of 1% goat 
serum in 1X PBS was used for blocking non-specific antibody binding for 15 min 
at room temperature. 10 µl of an anti-CXCR2-specific monoclonal antibody, 
phycoerythrin (PE)-conjugated mouse monoclonal anti-human IL-8 receptor B 
(R&D systems, MN), was added to the cells for 1 hr at RT in the dark. After 
washing with 4 ml 1X PBS, 200 µl strepavidin-fluorescein isothiocyanate (FITC) 
(1:200 dilution) (BD Biosciences, CA) was added to the cells for 1 hr at RT in the 
dark, followed by an additional washing. Fixation of the cells was performed with 
200 µl 4% paraformaldehyde (PFA). A BD FACSCaliburTM (BD Sciences) was 
used to obtain flow cytometry data from the immunostained samples. The flow 
cytometry data were analyzed by FlowJo 8.7 software (Tree Star Inc., OR).  
 
Homology modeling of human CXCR2 
To construct a homology modeled CXCR2, published crystal structures of 
bovine rhodopsin (Protein Data Bank (PDB) code: 1U19), β2AR (PDB code: 
2RH1), and CXCR4 (PDB code: 3ODU) were used as templates. Homology 
modeling was performed in Molecular Operating Environment (MOE 2008.10) of 
chemical computing group (Montreal, Canada). Sequence alignments of CXCR2 
and the three templates were performed using BLOSUM30 matrix, a gap open 
penalty of 10.0 and a gap extension penalty of 0.05. The results of alignments 
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was evaluated by using the highly conserved residues on class A GPCR family, 
including the (D/E)R(Y/W) motif in TM3, the Cys residues on the boundary of 
EC1 and TM3 and within the EC2 that form disulfide bridges and the NPXXY 
motif in TM7. The formation of disulfide bridges was induced by automatic search 
option. The backbone atoms on transmembrane regions were kept fixed and 
remaining residues are refined by energy-minimization with assisted model 
building with energy refinement (Amber)-99 force fields. Root mean square 
deviation (RMSD) was calculated to evaluate structural similarity and differences 
between homology modeled CXCR2 and templates. Furthermore, Site Finder in 
MOE software was used to search possible binding sites for ligands. 
 
Prediction of secondary structure of GPCRs 
Structures of the second extracellular loops were predicted by two web-
based programs, the self-optimized prediction method (SOPMA) of the network 
protein sequence analysis (NPS@) (128) and the web server for protein surface 
accessibility and secondary structure predictions (NetSurfP ver. 1.1) of center for 
biological sequence analysis (CBS) (129). 
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Table 3. Primers for cysteine-scanning mutagenesis on different regions of 
CXCR2 
Region Name Forward primer Reverse primer 
N-ter D9C 5’- CATGGAGAGTtgtAGCTTTGAAGATTTCTGGAAAGGTG-3’ 5’- CAAAGCTacaACTCTCCATGTTAAAATC-3’ 
IC1 G79C 5’-GTCtgcCGCTCCGTCACTGATGTCTACCTGCTG-3’ 5’-GTGACGGAGCGgcaGACCCTGCTGTATAAGATGAC-3’ 
TM4 L182C 5’-GTCTTAtgcTTCCGAAGGACCGTCTACTC-3’ 5’-CGGTCCTTCGGAAgcaTAAGACAGGCAGGGC-3’ 
 F183C 5’-CTTACTTtgcCGAAGGACCGTCTACTCATC-3’ 5’-CGGTCCTTCGgcaAAGTAAGACAGGCAGGGC-3’ 
EC2 R184C 5’-CTTTTCtgcAGGACCGTCTACTCATCCAATG-3’ 5’-CGGTCCTgcaGAAAAGTAAGACAGGCAGGGC-3’ 
 R185C 5’-CGAtgcACCGTCTACTCATCCAATGTTAGC-3’ 5’-GTAGACGGTgcaTCGGAAAAGTAAGACAGGC-3’ 
 T186C 5’-CGAAGGtgcGTCTACTCATCCAATGTTAGC-3’ 5’-GAGTAGACgcaCCTTCGGAAAAGTAAGACAGGC-3’ 
 V187C 5’-GAAGGACCtgcTACTCATCCAATGTTAGCCCAGC-3’ 5’-CATTGGATGAGTAgcaGGTCCTTCGGAAAAG-3’ 
 Y188C 5’-CGTCtgcTCATCCAATGTTAGCCCAGCCTGC-3’ 5’-CATTGGATGAgcaGACGGTCCTTCGGAAAAG-3’ 
 S189C 5’-CTACtgcTCCAATGTTAGCCCAGCCTGCTATG-3’ 5’-CATTGGAgcaGTAGACGGTCCTTCGGAAAAG-3’ 
 S190C 5’-CTCAtgcAATGTTAGCCCAGCCTGCTATGAG-3’ 5’-GCTAACATTgcaTGAGTAGACGGTCCTTCGGAAAAG-3’ 
 N191C 5’-CATCCtgcGTTAGCCCAGCCTGCTATGAGGAC-3’ 5’-GCTAACgcaGGATGAGTAGACGGTCCTTCGAAAAG-3’ 
 V192C 5’-CAATtgcAGCCCAGCCTGCTATGAGGACATG-3’ 5’-GCTGGGCTgcaATTGGATGAGTAGACGGTCCTTCG-3’ 
 S193C 5’-CAATGTTtgcCCAGCCTGCTATGAGGACATG-3’ 5’-GCTGGgcaAACATTGGATGAGTAGACGGTCCTTCG-3’ 
 P194C 5’-GTTAGCtgcGCCTGCTATGAGGACATGGGCAAC-3’ 5’-CATAGCAGGCgcaGCTAACATTGGATGAGTAGACG-3’ 
 A195C 5’-GCCCAtgcTGCTATGAGGACATGGGCAAC-3’ 5’-CATAGCAgcaTGGGCTAACATTGGATGAGTAGACG-3’ 
 Y197C 5’-CTGCtgcGAGGACATGGGCAACAATACAGCAAAC-3’ 5’-CATGTCCTCgcaGCAGGCTGGGCTAACATTGGATG-3’ 
 E198C 5’- GCCTGCTATtgtGACATGGGCAACAATACAGC-3’ 5’- GTTGCCCATGTCacaATAGCAGGCTGGGCTAAC-3’ 
 D199C 5’- CTATGAGtgtATGGGCAACAATACAGCAAAC-3’ 5’- GTTGCCCATacaCTCATAGCAGGCTGGGCTAAC-3’ 
 M200C 5’-GAGGACtgcGGCAACAATACAGCAAACTGGC-3’ 5’-GTTGCCgcaGTCCTCATAGCAGGCTGGGCTAAC-3’ 
 G201C 5’-CATGtgcAACAATACAGCAAACTGGCGGATGC-3’ 5’-GCTGTATTGTTgcaCATGTCCTCATAGCAGGC-3’ 
 N202C 5’-CATGGGCtgcAATACAGCAAACTGGCGGATGC-3’ 5’-GCTGTATTgcaGCCCATGTCCTCATAGCAGGC-3’ 
 N203C 5’-CAACtgcACAGCAAACTGGCGGATGCTG-3’ 5’-GCTGTgcaGTTGCCCATGTCCTCATAGCAGGC-3’ 
 T204C 5’-CAACAATtgcGCAAACTGGCGGATGCTGTTAC-3’ 5’-GCCAGTTTGCgcaATTGTTGCCCATGTCCTC-3’ 
 A205C 5’-CAACAATACAtgcAACTGGCGGATGCTGTTAC-3’ 5’-GCCAGTTgcaTGTATTGTTGCCCATGTCCTC-3’ 
 N206C 5’-CAGCAtgcTGGCGGATGCTGTTACGGATCCTG-3’ 5’-GCATCCGCCAgcaTGCTGTATTGTTGCCCATG-3’ 
 W207C 5’-GCAAACtgcCGGATGCTGTTACGGATCCTG-3’ 5’-CAGCATCCGgcaGTTTGCTGTATTGTTGC-3’ 
 R208C 5’-GCAAACTGGtgcATGCTGTTACGGATCCTGCCCCAG-3’ 5’-CAGCATgcaCCAGTTTGCTGTATTGTTGCCCATGTC-3’ 
 M209C 5’-CTGGCGGtgcCTGTTACGGATCCTGCCCCAG-3’ 5’-GTAACAGgcaCCGCCAGTTTGCTGTATTGTTG-3’ 
 L210C 5’-CGGATGtgcTTACGGATCCTGCCCCAGTC-3’ 5’-GATCCGTAAgcaCATCCGCCAGTTTGCTGTATTG-3’ 
 L211C 5’-GCTGtgcCGGATCCTGCCCCAGTCCTTTGGC-3’ 5’-CAGGATCCGgcaCAGCATCCGCCAGTTTGCTG-3’ 
 R212C 5’-GCTGTTAtgcATCCTGCCCCAGTCCTTTGGC-3’ 5’-CAGGATgcaTAACAGCATCCGCCAGTTTGCTG-3’ 
 I213C 5’-GTTACGGtgcCTGCCCCAGTCCTTTGGCTTCATCG-3’ 5’-CTGGGGCAGgcaCCGTAACAGCATCCGCCAGTTTG-3’ 
 L214C 5’-CGGATCtgcCCCCAGTCCTTTGGCTTCATCG-3’ 5’-CTGGGGgcaGATCCGTAACAGCATCCGCCAG-3’ 
Uppercase sequences in the forward and reverse primers above indicate original 
nucleotides of CXCR2 and red lowercase sequences are for the site-direct 
cysteine amino acid mutation. 
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Chapter 4 Results  
 
Structural similarity and differences between homology modeled 
CXCR2 and crystal structures of GPCRs 
Sequence alignment and homology modeling for CXCR2 were performed 
with bovine rhodopsin, β2AR, and CXCR4 in MOE software. Sequence 
alignments with rhodopsin and β2AR showed low identity in the alignment (18.1% 
for rhodopsin, 24.2% for β2AR), whereas CXCR4 provided relatively high identity 
(33.3%) to CXCR2 (Fig. 7, 8, 9). In all the cases, the (D/E)R(Y/W) and NPXXY 
motifs are conserved in their primary sequences. The modeling produced a 
rhodopsin-based CXCR2 model (bRho-CXCR2), a β2AR-based model (b2AR-
CXCR2), and a CXCR4-based model (CXCR4-CXCR2) (Fig. 10). All three 
models contain the highly conserved disulfide bond of GPCRs however the 
CXCR4-based model has one more disulfide bond linking amino terminus and 
third extracellular loop. Like their templates, bRho-CXCR2 and CXCR4-CXCR2 
produced two β-strands in its second extracellular loop, whereas b2AR-CXCR2 
showed only one α-helix.  
To evaluate structural similarity of homology modeled CXCR2 structures 
and crystal structures of GPCRs, superposition of the structures were performed 
and RMSD values of seven transmembrane helices were measured (Fig. 11). 
Zero at RMSD means they are identical in conformation. The bRho-CXCR2 
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showed the lowest value (1.64 Å) in the comparison with rhodopsin, the b2AR-
CXCR2 was the most identical to β2AR (2.02 Å), and CXCR4-CXCR2 was very 
similar to CXCR4 (0.78 Å). Interestingly, the RMSD from CXCR4-CXCR2 versus 
CXCR4 was the lowest among comparison of the models with their own 
templates. The highest RMSD value (2.93 Å) was derived from the comparison of 
b2AR-CXCR2 and CXCR4. Furthermore, Site Finder was used to predict ligand 
binding sites of b2AR-CXCR2 and CXCR4-CXCR2 (Fig. 12). The prediction 
indicates that residues in all the extracellular loops are highly associated with 
ligand binding. Residues in some of transmembranes domains showed the 
involvement in ligand binding as well. 
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Figure 7. Sequence alignment of CXCR2 and bovine rhodopsin. 
Identical residues are represented with color boxes. CXCR2 shows 18.1% 
(65/360 amino acids) identity with rhodopsin. Both have the highly conserved 
(D/E)R(Y/W), NPXXY motif, and rotamer toggle switch (#) (red texts and boxes), 
whereas only bovine rhodopsin has a Glu residue in its IC3 forming an ionic lock 
between TM3 and TM6. In the EC2 of rhodopsin, there are two β-strand 
structures (Green). Asterisks indicate the Cys residues that form a conserved 
disulfide bond in GPCRs. Each motif of rhodopsin and CXCR2 were based on 
crystal structure of rhodopsin (PDB code: 1U19) and prediction of universal 
protein resource (Uniprot, www.uniprot.org), respectively. 
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Figure 8. Sequence alignment of CXCR2 and β2AR. 
Identical residues are represented with color boxes. CXCR2 shows 24.2% 
(87/360 amino acids) identity with β2AR. Both share the highly conserved 
(D/E)R(Y/W), NPXXY motif, and rotamer toggle switch (#) (red texts and boxes), 
whereas a Glu residue in its IC3 forming an ionic lock between TM3 and TM6 
only conserved in β2AR. In the EC2 of β2AR, there are two α-helices structures 
(blue). Asterisks indicate the Cys residues that form a conserved disulfide bond 
in GPCRs. Each motif of β2AR and CXCR2 were based on crystal structure of 
β2AR (PDB code: 2RH1) and prediction of universal protein resource (Uniprot, 
www.uniprot.org), respectively.
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Figure 9. Sequence alignment of CXCR2 and CXCR4. 
Identical residues are represented with color boxes. CXCR2 shows 33.3% 
(120/360 amino acids) identity with CXCR4. Their EC2s shared few amino acids 
(16% identity, 4/25 amino acids). Both share the highly conserved (D/E)R(Y/W), 
NPXXY motif, and rotamer toggle switch (#) (red boxes). However, CXCR2 and 
CXCR4 has no a Glu residue in its IC3 forming an ionic lock between TM3 and 
TM6 conserved in rhodopsin and β2AR. In the EC2 of CXCR4, there are two β-
strand structures (green). There are two disulfide bonds (* and &) in the GPCRs. 
Each motif of CXCR4 and CXCR2 were based on crystal structure of CXCR4 
(PDB code: 3ODU) and prediction of universal protein resource (Uniprot, 
www.uniprot.org), respectively.
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Figure 10. Homology modeled CXCR2 structures based on the crystal 
structures of bovine rhodopsin, human β2AR, and human CXCR4. 
Three homology models for CXCR2 based on three crystallized GPCRs: (A) 
rhodopsin-based CXCR2 structure (B) β2AR-based CXCR2 structure (C) 
CXCR4-based CXCR2 structure. The homology models share a conserved 
disulfide bond linking TM3 and EC2, but only CXCR4 and CXCR2 have one 
more disulfide bond linking amino terminus and EC3 (yellow).  
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Figure 11. Superposition and structural similarity of homology modeled 
CXCR2 structures with other GPCRs. 
(A) Transmembranes domains of the rhodopsin-based CXCR2 model (red) were 
superimposed with the crystal structure of rhodopsin (gray). Most of the residues 
in the transmembranes showed below pairwise root mean squared deviations 
(RMSD) 2.0 Å, except for Gly65 (orange) in TM1 (3 amino acids gap in sequence 
alignment) and Phe97 to W104 (purple) in TM2 (2 amino acids gap in sequence 
alignment). (B) Superposition of transmembranes of the β2AR-based CXCR2 
model (green) and its template, β2AR (gray) was performed. Most of the residues 
in the transmembranes showed below RMSD 2.0 Å, except for Lys48 (orange) to 
Val52 in TM1 and Ala177 to Phe183 (purple) in TM4 (1 amino acid gap in 
sequence alignment). (C) Seven transmembranes of the CXCR4-based CXCR2 
(purple) were superposed with the CXCR4 crystal structure (gray). None of the 
residues in transmembranes are over RMSD 2.0 Å. (D) The RMSDs were 
measured with the seven transmembrane helices of crystallized GPCRs and 
homology models of CXCR2. Transmembranes regions were determined by 
multiple sequence alignment with their primary sequences.  
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Figure 12. Prediction of ligand binding sites in β2AR-based and CXCR4-
based CXCR2 structure. 
The Site Finder in Molecular Operation Environment (MOE) software was used to 
search for potential ligand binding sites in β2AR-based CXCR2 (A) and CXCR4-
based CXCR2 models (B). Spheres indicate possible contact sites for ligand 
binding (red = hydrophilic, white = hydrophoblic). (A) In the β2AR-based CXCR2, 
most of the residues in the predicted binding site are localized in the extracellular 
loops, including Lys108, Val109, Asn110, Gly111, and Trp112 in the first 
extracellular loop, Arg184, Arg185, Cys196, Tyr197, Glu198, Asp199, Met200, 
and Thr204 in the second extracellular loop (yellow), and Glu284, Thr285, 
Cys286, Arg289, Asn290, Asp293, and Leu296 in the third extracellular loop. 
Furthermore, some transmembranes residues were predicted as binding sites, 
including Phe97, Thr100, Ile103, Trp104, and Ser107 in the second 
transmembrane, Cys119, Val122, Ser123, Lys126, Glu127, and Phe130 in the 
third transmembrane, and Phe218, Trp264, Tyr267, and Leu271 in the fifth 
transmembrane. (B) CXCR4-based CXCR2 also has many residues in 
extracellular domains as potential ligand binding sites; Glu40, Pro41, Glu42, and 
Lys48 in the amino terminus, Trp104, Ser107, Lys108, Val109, Asn110, Gly111, 
and Trp112 in the first extracellular loop, and Arg184, Arg185, Thr186, Tyr188, 
Ser190, Asn191, Val192, Ser193, Pro194, Ala195, Cys196, Tyr197, Glu198, 
Asp199, Arg208, Leu211, and Arg212 in the second extracellular loop. 
Furthermore, several residues in the transmembrane domains were predicted as 
ligand binding sites: Tyr55 in the first transmembrane, Phe97 and Leu101 in the 
second transmembrane, Val122, Ser123, Lys126, Glu127, and Phe130 in the 
third transmembrane, Val180 in the fourth transmembrane, Pro215 and Gln216 
in the fifth transmembrane, Tyr267, Leu271, Asp274, and Arg278 in the sixth 
transmembrane, and Arg289, Ile292, Asp293, Arg294, Leu296, Asp297, Glu300, 
Ile301, and Ile304 in the seventh transmembrane. 
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Secondary structure of the second extracellular loop of CXCR2 
Structures of the second extracellular loops of different GPCRs including 
bovine rhodopsin (bRho), human β2-AR (beta2AR), CXCR4, and CXCR2 were 
predicted by SOPMA of NPS@ and NetSurfP (ver. 1.1) (Fig. 13). The predictions 
for bovine rhodopsin, β2-adrenergic receptor, and CXCR4 were compared with 
their crystal structures to evaluate the accuracy of their predictions. In rhodopsin, 
the prediction of the NetSurfP was very similar with its crystal structure with the 
accuracy of a kind of secondary structure, number of secondary structures and 
position of the structures. The α-helix in EC2 of β2-AR was predicted by 
NPS@SOPMA, although the sequence length of the predicted helix was very 
short. In CXCR4, both methods showed two β-strands like its crystal structure.  
Based on the accuracy of two methods for secondary structure prediction, 
the secondary structure EC2 of CXCR2 was predicted and aligned with that of 
CXCR4-based CXCR2 (CXCR4-CXCR2).  Like the CXCR4-based CXCR2 
model, two methods provided showed two β-strands. Especially, structure 
predictions for amino acids surrounding Cys196, a highly conserved cysteine 
forming disulfide bind with Cys119, were very similar with each other (in 
NSP@SOPMA, NetSurfP, and homology modeling). Furthermore, the predictions 
showed beginning of the fifth transmembrane of CXCR2, which is important for 
defining the boundary of the second extracellular loop of CXCR2.  
The second extracellular loop of the CXCR4-based CXCR2 model was 
superimposed with that of the CXCR4crystal structure. The superimposition 
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showed the second extracellular loop of CXCR2 is structurally very similar with 
that of CXCR4 (below 2.0 Å RMSD per residue, 0.6 Å RMSD in total), with an 
exception of Asn203 of CXCR2 (Asp193 of CXCR4) (over 2.0 Å RMSD per 
residue). 
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Figure 13. Prediction of secondary structure of the second extracellular 
loop of CXCR2 
A) Structures of the second extracellular loops of several GPCRs including 
bovine rhodopsin (bRho), β2-adrenergic receptor (beta2AR), CXCR4, and 
CXCR2 were predicted by using NPS@SOPMA and NetSurfP (ver. 1.1). The 
predictions for bovine rhodopsin, β2-adrenergic receptor, and CXCR4 were also 
compared with their crystal structures. The predicted secondary structure of the 
EC2 of CXCR2 was aligned with that of CXCR4-based CXCR2 (CXCR4-CXCR2). 
Color code was used to show secondary structures: h = α-helix, e = β-strand, t = 
turn, and c = coil. Cys residues that form a conserved disulfide bond were 
indicated with specific signs (* for rhodopsin, β2AR, CXCR4, and CXCR2, # for 
intra disulfide bond in only β2AR). B) The structures of the second extracellular 
loops of CXCR4 and CXCR4-based CXCR2 model were superimposed with 
each other. All of the residues in the EC2 of CXCR2 except for Asp203 (over 2.0 
Å RMSD, compared with Asp193 of CXCR4) were structurally very similar to 
CXCR4. Two cysteine residues (Cys119 and Cys196) forming a conserved 
disulfide bond were represented. 
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Solvent accessibility of residues on the second extracellular loop of 
CXCR2 in the inactive state 
Wild-type CXCR2 and single cysteine mutant receptors were transiently 
transfected into HEK293 cells. After 48 h of cultivation, whole cells were 
harvested and exposed to MTSEA-biotin for labeling of water-accessible cysteine 
residues. Cell surface-expressed CXCR2 receptors and MTSEA-biotin labeled 
receptors were immunostained with an anti-CXCR2 antibody and streptavidin-
FITC, respectively. Flow cytometry was used to show solvent accessibility of 
individual CXCR2 receptors mutants. Accessibility values of wild-type CXCR2 
and single cysteine mutant receptors were calculated from the mean 
fluorescence intensity (MFI) of FITC (detects accessibility of an additional Cys 
residue) divided by MFI of PE (detects total cell surface expression level of 
CXCR2 receptors). The relative accessibility values were derived from 
accessibility values of the mutant receptors fold over that of wild-type. A 
representative graph was drawn for the relative accessibility values (Fig. 14). 
The experiment reveals that residue D9C in the amino terminus of 
CXCR2, is solvent exposed, whereas residue G79C in the first intracellular loop 
is not water accessible. L182C and F183C which are predicted to be in the fourth 
transmambrane (TM4) showed similar or less solvent accessibility compared with 
that of wild-type CXCR2. Residues of the second extracellular loop are divided 
into two groups by their location relative to residue Cys196 that is critical for a 
highly conserved disulfide bond found in class A GPCRs. The front group is from 
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R184C to A195C and the rear group is from Y197C to L214C. Although there is 
fluctuation between accessibility values, all of the residues in the front group of 
EC2 are solvent exposed. Interestingly, in the rear group of EC2, Y197C next to 
Cys196 and the penta-amino acids, T204 to R208, showed similar water 
accessibility with wild-type CXCR2 and the rest of the rear group are solvent 
exposed. The solvent accessibility of I213C close to the fifth transmembrane 
(TM5) was the highest in our experiment. 
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Figure 14. Solvent accessibility maps of the single cysteine mutants of 
CXCR2.  
Each color box indicates different regions of mutant CXCR2 with a cysteine 
substitution. Red box represents the D9C mutant receptor in the amino terminus, 
yellow is G79C with a single mutation in the first intracellular loop (IC1), green 
contains two fourth transmembrane (TM4) mutants (L182C and F183C), and blue 
has all the mutants for the residues in the second extracellular loop (EC2). 
Statistical analysis was calculated by student t-test with statistical significance (*) 
set at P<0.05. 
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Chapter 5 Discussion 
 
Crystal structures of GPCRs have been used to predict structures of other 
GPCRs that have not been solved (32, 41, 42). Homology modeling for CXCR2 
using the crystallized bovine rhodopsin have been attempted to explain 
experiments of receptor stabilization and antagonism (32, 41, 42, 84, 102). 
However, their observations about the predicted CXCR2 models focused on 
some limited regions of interested (e.g. second extracellular loop and seventh 
transmembrane). Furthermore, their homology modeled CXCR2 structures were 
not evaluated through the comparison with more recent crystal structures of other 
GPCRs.  
In this study, we performed homology modeling for CXCR2 by using three 
crystallized GPCRs, rhodopsin, β2AR and CXCR4. Sequence alignments 
between them showed conservation of highly conserved motifs (e.g. 
(D/E)R(Y/W), NPXXY, and toggle switch), pointing to the possibility of using the 
three crystal structures as templates for the homology modeling (Fig. 7, 8, 9). 
Furthermore, the motifs and alignments were used to compare locations and 
length of transmembrane helices for evaluation of homology modeled CXCR2. 
The highly conserved disulfide bond linking TM3 and EC2 was automatically 
generated during the homology modeling process in all the models, but only the 
CXCR4-based CXCR2 model has one more disulfide bond linking the amino 
terminus and EC3. The homology modeled structures are intended to show 
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structural similarity with their templates. Especially since the secondary 
structures in the second extracellular loops were the same as their original 
templates (e.g. β-strands of rhodopsin and α-helix of β2AR) (Fig. 10) and their 
RMSD values also represented the intention (Fig. 11). However, we made use of 
β2AR and CXCR4 as a template for homology modeling, even though they have 
some structural modifications that interrupt modeling for other GPCRs (e.g. 
fusion with T4 lysozyme in the third intracellular loop in both structures, and an 
intra-disulfide bond in the second extracellular loop found only in β2AR). Even 
though all three crystallized GPCR stuctures were used as templates and 
showed significant structural conservation in transmembrane domains, CXCR4 
might be the best template for CXCR2 based on high identity (33.3%) in 
sequence alignment and the lowest RMSD values (0.78Å) in structure 
superposition (Fig. 9,10). Furthermore, two secondary structure prediction 
programs, NPS@SOPMA and NetSurfP were used to predict the secondary 
structure of the second extracellular loop of CXCR2. In three GPCRs including 
rhodopsin, β2AR, and CXCR4, the programs showed highly accurate results in 
the comparison of crystal structures and their predictions. The prediction of the 
programs suggested that the second extracellular of CXCR2 has two β-strands 
like rhodopsin and CXCR4. Similarly, the CXCR4-based CXCR2 model 
suggested two β-strands, even though CXCR2 and CXCR4 have very low 
identity between the residues in their second extracellular loops. Interestingly, the 
superimposition of CXCR4-based CXCR2 and CXCR4 suggested that the 
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structure of the second extracellular loop of the CXCR2 model might be very 
similar with CXCR4 (Fig. 13). 
We also studied the topology of residues in the EC2 of CXCR2 by using 
substituted-cysteine accessibility method (SCAM), due to the importance of this 
region in ligand binding and potential receptor activation. Unlike the common 
SCAM process with immunoblotting (9, 130), flow cytometric analysis was 
performed to amplify signals of FITC-streptavidin bound MTSEA-biotin. 
Furthermore, cell surface expression levels of mutant receptors that are needed 
to normalize MTSEA-biotin accessibility were measured at the same time 
through immunostaining with a specific antibody against CXCR2. The refined 
approach was evaluated by the accessibility of several mutant receptors 
including D9C (amino terminus), G79C (IC1), L182C (TM4), and F183C (TM4). 
Our SCAM results indicate that most of the residues in EC2 are water-
accessible in the inactive state of CXCR2 (in the absence of ligand) (Fig. 14). 
Especially, all the charged residues (R184C, R185C, E198C, D199C, and 
R212C) in EC2 except for R208C are exposed to solvent. Because charged 
residues on the extracellular loops were considered as key residues to form a 
binding pocket, ligands of CXCR2 could contact the exposed residues followed 
by receptor activation. In the study to find CXCL8 binding sites to homology 
modeled CXCR2 structures, most of the residues in EC2 including the charged 
residues were predicted as potential key residues (Fig. 12). In EC2, five 
sequential amino acids 204TANWR208 were predicted as non-accessible residues. 
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These residues might be involved in the interaction with the amino terminus or 
other extracellular loops. Since the CXCR2 models lack an amino terminus, there 
are limitations to studying the mechanisms for ligand binding and receptor 
activation. Thus our interdisciplinary approaches and observations would be very 
helpful to plan new approaches to discover unknown mechanisms about CXCR2. 
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PART III  
INVOLVEMENT OF THE SECOND EXTRACELLULAR 
LOOP OF CXCR2 IN LIGAND RECOGNITION AND 
RECEPTOR ACTIVATION 
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Chapter 1 Abstract 
 
It has been shown that the amino terminus and second extracellular loop 
of CXCR2 are crucial for ligand binding and receptor activation. The lack of an 
ionic lock motif (a Glu residue) in the third intracellular loop in CXCR2 focuses an 
investigation of two extracellular regions in CXCR2 involved in receptor 
recognition and activation. Using constitutively active mutants, D9K and D9R, in 
CXCR2, the potential role of charged residues in the second extracellular loop of 
CXCR2 was investigated.  
Combinatorial mutations consisting of the constitutively active mutants in 
the amino terminus and single mutations of charged residues in the second 
extracellular loop were generated to study two concepts including “attraction” and 
“repulsion” models. The mutant receptors were used to test their effects on cell 
surface expression, ligand binding, receptor activation through PLC-β3, and 
cellular transformation. All the mutations in the repulsion model result in CXCR2 
receptors that are unable to bind ligand, indicating that all the Arg residues 
(Arg184, Arg185, Arg208, and Arg212) in the second extracellular loop are 
important for ligand recognition. Although charge-reversal complementary 
mutations in the repulsion model were expected to retain structural constraints of 
CXCR2, none of the mutant receptors function as wild-type CXCR2 in the 
inactive and active states. Interestingly, mutations in the attraction model partially 
inhibited receptor activation of constitutively active mutant D9K, suggesting that 
Glu198 and Asp199 residues in the second extracellular loop are highly 
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associated with receptor activation. Furthermore, a novel constitutively active 
mutant E198A/D199A was identified in this study. These negatively charged 
residues are very close to a disulfide bond (Cys119-Cys196) linking the second 
extracellular loop and the third transmembrane. The unique location suggests 
that the neutralization (with Ala residues) of the residues might be needed to 
control TM3 promote slight breakdown of structural constraint of the constitutively 
activated CXCR2 with D9K mutation.  
These observations are helpful to understand how the extracellular 
regions of CXCR2 interact with its cognate ligands and transfer signals 
intracellularly. 
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Chapter 2 Introduction 
 
GPCRs respond to a variety of ligands that are classified into agonist and 
antagonist. GPCRs can also induce constitutive activation in the absence of 
external ligands. Single point mutations of GPCRs as well as some wild-type 
GPCRs have been shown to lead to constitutively activity (131). Moreover, the 
constitutively active mutants of GPCRs have been used as important 
pharmacological targets for the development of potent drugs against mutant 
GPCR-mediated diseases (132).  
In class A GPCRs, it has been shown that the highly conserved 
(D/E)R(Y/W) motif in TM3 is important for interaction with D/E residue at the 
boundary of IC3 and TM6 (38). The interaction, also called the ‘ionic lock’, is 
crucial to stabilize the inactive conformation of GPCR receptors. Mutations of 
these residues result in an increase of constitutive activity (39, 133). 
Furthermore, breakage of the ionic lock is linked to turning on the ‘toggle switch’ 
in TM6, with the change of configuration of a conserved Pro residue surrounding 
aromatic residues in TM6 (38). These mechanisms for receptor activation are 
conserved in both rhodopsin and β2AR have been well studied. However, in most 
(~80%) of class A GPCRs, residues for the ionic lock or toggle switch are not 
present (133). 
Currently, novel mechanisms for receptor activation have been found. The 
first example is a model with ionic locks on the extracellular surface (134). Free 
fatty acid receptor 1 (FFAR1) does not contain residues for both an ionic lock and 
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toggle switch similar to rhodopsin and β2AR. FFAR1 contains a Lys instead of a 
Glu in TM6 (for an ionic lock) and a Val and Asn rather than the aromatic 
residues in TM6 (for a toggle switch). Interestingly, homology modeling of FFAR1 
showed two ionic locks between two Glu residues on EC2 and two Arg residues 
on distinct transmembranes including TM5 and TM7. Single alanine mutations for 
the two Glu on EC2 induced constitutive activation of the receptor in the absence 
of ligand, indicating that the EC2 of the receptor can participate in receptor 
activation. Furthermore, a random mutagenesis study of residues on EC2 of the 
complement factor 5a receptor (C5aR), a class B GPCR, showed that multiple 
residues in EC2 are highly associated with receptor stabilization in the inactive 
state (36). 
A second example is the role of conserved Cys residues in the amino 
terminus and third extracellular loop (EC3) of chemokine receptors (135). CXCR4 
was used as a model to substitute a Ser pair, aromatic pair (Phe), or salt bridge 
pair (Arg/Asp) for the conserved Cys residues. The mutation with a Ser pair in a 
constitutively active mutant (CAM) CXCR4 (N119S) disrupted the receptor 
activation, whereas the other substitutions with the Phe or Arg/Asp pair in the 
CAM CXCR4 showed little effect on the constitutively activity of the receptor. The 
result suggested that the disufide bond derived from the conserved Cys in the 
amino terminus and EC3 of chemokine receptors is important for receptor 
activation and signaling. 
CXCR2 shares the highly conserved (D/E)R(Y/W) motif like other GPCRs 
in class A. A point mutation of Asp143 (to Val, the same with KSHV-GPCR) of 
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the motif on CXCR2 leads to constitutive activation of the receptor and cellular 
transformation similar to KSHV-GPCR (118). However, like FFAR1 (Lys219), 
CXCR2 has Lys246 instead of D/E residue in TM6 to interact with Arg of the 
(D/E)R(Y/W) motif for an ionic lock, whereas aromatic residues (Trp264 and 
Tyr267 in TM6 of CXCR2) for a toggle switch are conserved in TM6. This 
suggests that CXCR2 is different in the mechanism for receptor activation 
compared to rhodopsin and β2AR. In a previous study of the role of EC2 in 
activation and regulation of the receptor, it has been shown that mutation of 
Asp199 (to Val) in EC2 delayed the internalization of the receptor, whereas 
substitution with Asn restored the internalization speed (84). With homology 
modeling of CXCR2 based on rhodopsin, the study suggested that Asp199 
functions to stabilize the receptor conformation using hydrogen bonds between 
several residues (Arg185, Thr186, and Arg208) in EC2. Currently, it has been 
shown that single point mutations of Asp9 in the amino terminus of CXCR2 leads 
to constitutive activation to promote cellular transformation activity in cells stably 
expressing the mutant receptors (Park et al., unpublished). The study also 
demonstrated that different constitutive active mutants show signal specificity. 
Taken together, these observations suggest that both the amino terminus and 
EC2 of CXCR2 are crucial in receptor activation. 
Viral oncogene ORF74 encoded by Kaposi’s sarcoma-associated 
herpesvirus (human herpesvirus 8), also called KSHV-GPCR, is the closest 
homolog to CXCR2 (103). KSHV-GPCR constitutively activates AP-1, CREB, 
NFAT, and MAPK via Gαi or Gαq, and NF-κB through only Gαq subtype in 
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different cell lines including COS-7, primary effusion lymphoma (PEL), and 
endothelial cells (104-107). Currently, studies of M33 of murine cytomegalovirus 
(MCMV) and US28 of human cytomegalovirus (HCMV), viral GPCR homologs, 
have been shown that Gαq protein is activated to induce phopholipase C-β (PLC-
β) activity, followed by stimulation of CREB and NF-κB signals (108-111). 
Additionally, M33 can induce CREB and NF-κB stimulation via a PLC-β 
independent manner (112). On the other hand, another GPCR homolog UL33 of 
HCMV enhances CREB transcriptional activities by Gs pathway not Gq/11 pathway 
(113).  
As stated previously, a point mutation of Asp143 to Val in the highly 
conserved (D/E)R(Y/W) motif in CXCR2 leads to constitutive activation and 
cellular transformation (118). The transforming capacities were totally inhibited by 
using AG490, a specific kinase inhibitor of JAK2-STAT3 signaling (119). It has 
been demonstrated that the constitutive activity of KSHV-GPCR and CXCR2 
mutant D143V is highly associated with STAT3 phosphorylation. A current study 
of CXCR2 expressed in ovarian cancer cells reported that cancer growth is 
regulated by the MAPK and NF-κB pathways (121). Additionally, it was shown 
that the chemokine CXCL1 binding to CXCR2 but not CXCR1 induces 
transactivation of epidermal growth factor receptor (EGFR) via the chemokine 
receptor, followed by proliferation of ovarian cancer cells (122). 
In this study, we investigated a role of charged residues in EC2 of CXCR2 
in ligand binding and receptor activation. Two concepts, “attraction” and 
“repulsion” models were designed to investigate the mechanism of CXCR2 
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activation (Fig. 15). To end that, we constructed combinatorial mutation sets 
consisting of constitutively active mutants (CAM) Asp9 in the amino terminus and 
substitutions in EC2. These mutant receptors were generated by site-directed 
mutagenesis and transfected into mouse fibroblast NIH3T3 cell lines. The 
NIH3T3 cells stably expressing wild-type CXCR2 and mutant receptors were 
used to investigate cell surface expression of the receptor, ligand-binding, and 
receptor activation through phospholipase C-β3 (PLC-β3). 
 
  73 
 
 
 
Figure 15. Models of receptor activation of CXCR2 
This study used two models, attraction model (A) and repulsion model (B) to 
understand the mechanism of receptor activation of CXCR2.  
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CHAPTER 3 MATERIALS AND METHODS 
 
Cell lines and media 
NIH3T3 mouse fibroblast cells were cultured with DMEM containing 10% 
fetal clone 3 (FC3), 1X NEAA, and 1X penicillin/streptomycin. Transfectant 
NIH3T3 cells stably expressing wild-type CXCR2 or mutant receptors were 
maintained in the medium with 800 µg/ml G418, also known as Geneticin. 
 
Site-directed mutagenesis and transfection 
The CXCR2 gene cloned in pRc/CMV vector was used as a template for 
site-directed mutagenesis. Forward and reverse primers were manually designed 
for charged residues on EC2 of CXCR2 (Table 4). PCR mutagenesis was 
performed with a modification of the QuickChange® method (Stratagene). Dpn I 
digestion treatment was performed, followed by cleaning via a PCR purification 
kit. All mutations were conformed by sequencing analysis (Molecular biology 
resource facility, University of Tennessee, Knoxville).  
Plasmid DNAs of wild-type CXCR2 and mutant receptors were used to 
transfect NIH3T3 cells. The transfections were performed with Lipofectamine 
2000 reagent according to the manufacturer’s instructions. 4.0 x 105 NIH3T3 
cells were seeded in 6-well plates one day before transfection. 2 µg of plasmid 
DNA and 4 µl of Lipofectamine 2000 were individually diluted into 250 µl fresh 
DMEM, incubated for 5 min at room temperature, and mixed together followed by 
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incubation for 30 min at room temperature. The mixtures and 500 µl fresh DMEM 
were added to each well and incubated for 4 hr at 37 °C. The mixtures were 
substituted to new medium including 10% FC3, followed by cultivation for 48 hr at 
37 °C. Transfectant NIH3T3 cells stably expressing wild-type CXCR2 and mutant 
receptors were selected using the medium with 800 µg/ml G418. Single clonal 
cell lines were derived from the transfectants. An anti-CXCR2-specific 
monoclonal antibody, phycoerythrin (PE)-conjugated mouse monoclonal anti-
human IL-8 receptor B (R&D systems, MN), and flow cytometry were used to 
confirm the cell surface expression level of CXCR2 on the clonal cell lines. 
 
Ligand binding assay 
Competition ligand binding assays were performed as previously 
described (136). Wild-type CXCR2 and mutant receptors were transiently 
transfected into COS-7 cells. After 48 hr, binding was performed on whole cells 
for 3 hr at 4 °C using radio-labeled 125I-CXCL8 ligand in binding buffer (50 mM 
HEPES, pH 7.4, 1 mM CaCl2, 5 mM MgCl2, and 0.5% bovine serum albumin) and 
increasing amounts of unlabeled CXCL8. Washing was performed four times with 
binding buffer with 0.5 M NaCl at 4 °C. 
 
Immunostaining of phospho-PLC-β3 
The single clonal cell lines stably expressing wild-type CXCR2 or mutant 
receptors were used to measure serine phosphorylation (for Ser537) of PLC-β3. 
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4.0 x 105 cells were seeded in 60 mm dishes with the medium containing 10% 
FC3 and after one day the medium is substituted to fresh DMEM without serum. 
After 18-20 hr the cells were harvested with 2 ml 1X PBS using cell scraper, 
centrifuged at 400 g, and fixed with 100 µl fixation buffer BD CytofixTM for 15 min 
(BD Biosciences). The fixed cells were permeabilized with BDTM Phosflow Perm 
Buffer III (BD Biosciences) for 30 min on ice. A rabbit polyclonal antibody, p-PLC-
β3 (Santa Cruz Biotechnology, Inc., CA) (1:50 dilution) was added to the 
permeabilized cells for 1 hr at room temperature in dark. Alexa Fluor 488 goat 
anti-rabbit IgG antibody (Invitrogen, CA) (1:50,000) was used as secondary 
antibody to immunostain the cells for 1 hr at RT in dark. There was a washing 
with 4ml 1X PBS between each step. BD FACSCaliburTM (BD Sciences) was 
used to obtain flow cytometry data from the immunostained samples. The flow 
cytometry data were analyzed by FlowJo 8.7 software (Tree Star Inc., OR). 
 
Loss of contact inhibition (foci formation) assay 
The foci formation assay was performed by previously described (118). 
1.0 x 105 untransfected NIH3T3 cells were cultured in each well of a 6-well plate. 
After one day, 100 stable transfectants were seeded on top of the untransfected 
cells and maintained with serum-reduced medium containing 2% FC3. The cells 
were grown with or without inhibitors including PTX, U-73122, or AG490. Foci 
were counted after 2 weeks. 
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Chapter 4 Results 
 
Charged residues in the second extracellular loop of CXCR2 are 
required for ligand recognition 
To study the role of charged residues in second extracellular loop of 
CXCR2, negatively charged residues including Glu198 and/or Asp199 and 
positively charged residues such as Arg184, Arg185, Arg208, and Arg212 were 
substituted to Ala residue to neutralize their charges. The positively charged 
residues were also mutated to Asp residues in the charge-reversal manner. Non-
charged residues including Asn191, Asn202, and Asn203 were substituted to Ala 
as controls. The mutant constructs were generated by using site-directed 
mutagenesis and were conformed by sequence analysis.  
The wild-type CXCR2 and mutant receptors were transfected into mouse 
fibroblast NIH3T3 cell lines followed by single clonal selection. With NIH3T3 cells 
stably expressing the wild-type CXCR2 and mutant receptors, cell surface 
expression of the receptors was investigated by immunostaining with a specific 
antibody for CXCR2 (Table 4). There was no detectable difference in cell surface 
expression between wild-type CXCR2 and mutant receptors. 
To measure CXCL8-binding affinity to the wild-type CXCR2 and mutant 
receptors, the constructs were transiently transfected in COS-7 cell lines. 
Competition binding assays with radio-labeled 125I-CXCL8 were performed to 
determine ligand binding affinity (IC50) for each construct (Table 4). We found 
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that all the charged residues on EC2 of CXCR2, except for D199A, are involved 
in ligand binding. On the other hand, the mutations of Asn, an uncharged 
residue, in EC2 showed a similar level of binding affinity to the wild-type CXCR2 
receptor. 
 
Involvement of the amino terminus and second extracellular loop of 
CXCR2 in ligand recognition 
The combinatorial mutations containing the CAM D9 residue in the amino 
terminus and mutations of charged residues in EC2 of CXCR2 were transiently 
transfected into COS-7 cell lines to measure CXCL8 binding affinity. Competition 
ligand binding with radio-labled 125I-CXCL8 was performed for each construct 
(Table 4). Like the cases of the single mutations in EC2, all the combinatorial 
mutant receptors showed no binding to CXCL8. Interestingly, D9K/D199A 
showed no CXCL8 binding, whereas IC50 values of D9K and D199A individually 
are similar to wild-type CXCR2. 
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Table 4. CXCL8-binding and surface expression of wild-type CXCR2 and 
mutant receptors 
Receptor construct IC50 CXCL8 (nM)** Surface expression***  
Wild-type  CXCR2* 8.92±0.05 + 
N-ter D9K* 8.56±0.05 + 
 D9R* 8.69±0.21 + 
EC2 E198A > 1000 + 
 D199A 8.82±0.20 + 
 E198A/D199A > 1000 + 
 R184A N.D + 
 R185A N.D + 
 R208A N.D + 
 R212A N.D + 
 R184A/R185A N.D + 
 R184D > 1000 + 
 R185D > 1000 + 
 R208D > 1000 + 
 R212D > 1000 + 
 N191A 7.87±0.27 + 
 N202A 8.78±0.09 + 
 N203A 8.88±0.16 + 
 N202A/N203A 8.75±0.09 + 
N-ter and EC2 D9K/E198A > 1000 + 
 D9K/D199A > 1000 + 
 D9K/E198A/D199A > 1000 + 
 D9R/R184D > 1000 + 
 D9R/R185D > 1000 + 
 D9R/R208D > 1000 + 
 D9R/R212D > 1000 + 
*Data of wild-type CXCR2, D9K, and D9R were derived from Park et al., (Park et 
al., unpublished). 
** N.D = not determined 
>1000 =  the CXCL8 binding constants of certain mutant receptors were 
undetectable up to 1 µM. The sign >1000 means 1000-fold greater than IC50 of 
CXCL8 binding towild-type CXCR2. 
*** Surface expression was determined through immunostaining with an ant-
CXCR2 antibody and flow cytometric analysis. The wild-type CXCR2 and mutant 
receptors showed the very similar expression level (+). 
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Constitutively inactive mutants CXCR2 induced by charge-reversal 
complementary mutations (derived from repulsion model) 
Charge-reversal combinatorial mutant receptors consisting of CAM D9R 
and RxD mutations (R184D, R185D, R208D, and R212D) in EC2 were 
constructed to study whether the mutant receptors lead to constitutive activation 
like CAM D9R or change their structural constraints related to receptor function. 
Charge-reversal single mutations alone (R184D, R185D, R208D, and R212D) 
were used as controls. The NIH3T3 cells stably expressing the mutant receptors 
were used to investigate receptor activation by PLC-β3 signaling. The 
transfectants were immunostained with a specific PLC-β3 antibody to detect 
serine phosphorylation (Ser537 of PLC-β3). Flow cytometric analysis showed 
that CAM D9R induced significantly less phosphorylation than wild-type CXCR2 
(Fig. 16). Both the charge-reversal single and combinatorial mutant receptors 
showed more phosphorylated PLC-β3 than wild-type CXCR2, suggesting the 
inactivation of PLC-β3. 
To study whether the inactivation of PLC-β3 is involved in cellular 
transformation by the mutant receptors, foci formation assays were performed. 
None of the charge-reversal mutants formed foci, whereas CAM D9R 
significantly produced foci through constitutive activation (Fig. 17). Therefore, the 
charge-reversal single mutations as well as the combinatorial mutations lead to 
disruption of downstream signal transduction of CXCR2 through inhibition of 
PLC-β3 activity.  
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Negatively charged residues in EC2 of CXCR2 are highly associated 
with receptor activation of CXCR2 (derived from attraction model) 
The combinatorial mutant receptors consisting of CAM D9K and 
substitution of negatively charged residues to Ala (E198A, D199A, 
E198A/D199A) were constructed. The mutant receptors were used to investigate 
whether the mutant receptors retained constitutive activation like CAM D9K or 
induce some change related to receptor function. The transfectants stably 
expressing the mutant receptors were used to study receptor activation by PLC-
β3 signaling. Immunostaining and flow cytometric analysis with a specific PLC-β3 
antibody were performed for determining serine phosphorylation (Ser537 of PLC-
β3). In flow cytometric analysis, it was found that CAM D9K induced less PLC-β3 
phosphorylation than wild-type CXCR2 (Fig. 16). The combinatorial mutations 
(D9K/E198A, D9K/D199A, D9K/E198A/D199A) and double mutation 
(E198A/D199A) showed PLC-β3 phosphorylation levels between CAM D9K and 
untransfected NIH3T3. Especially, D9K/D199A had a very similar level to CAM 
D9K in phosphorylation of PLC-β3. On the other hand, two single mutant 
receptors (E198A and D199A) showed the same with untransfected NIH3T3. 
These indicate that the mutant receptors except for E198A and D199A induce 
activation of PLC-β3 like wild-type CXCR2, but showed some differences in PLC-
β3 activation levels. 
To study whether the activation of PLC-β3 by combinatorial mutant 
receptors leads to cellular transformation like CAM D9K, foci formation assays 
were performed. All the transfectants except for E198A and D199A formed foci, 
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but the number and size of foci were significantly smaller than CAM D9K (Fig. 
18). Furthermore, treatment with U-73122, an inhibitor of PLC-β signaling, 
prevented the formation of foci derived from all the combinatorial mutant 
receptors (Fig. 19). Therefore, the change of PLC-β3 activation levels might 
result in a partial reduction of the cellular transformation activity.  
 
A novel constitutively active mutant with double alanine mutations in 
CXCR2 
A novel CAM was identified among the mutations in EC2 of CXCR2. A 
double mutation E198A/D199A had cellular transformation activity, whereas the 
individual single mutations of negatively charged residues (E198A and D199A) 
did not (Fig. 16). Interestingly, the triple combinatorial mutant 
(D9K/E198A/D199A) consisting of two CAMs (D9K and E198A/D199A) rarely 
produced foci.  
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Figure 16. Phosphorylation of PLC-β3 in wild-type and mutant CXCR2 
receptors. 
These figures showed phosphorylation of PLC-β3 of CAM D9K and mutant 
receptors for the attraction model (A), CAM D9R and mutant receptors for the 
repulsion model (B, C, and D). 
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Figure 17. Foci formation assay with NIH3T3 transfectants stably 
expressing charge-reversal complementary mutant receptors derived from 
the repulsion model. 
Constitutively active mutant D9R was used for positive control. None of all the 
mutant transfectants showed foci formation. 
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Figure 18. Foci formation assay with NIH3T3 transfectants stably 
expressing combinatorial mutant receptors derived from the attraction 
model. 
A) Untransfected NIH3T3 cells were used as the negative control. E198A/D199A 
formed foci, whereas none of E198A and D199A showed a difference in 
background. B) Constitutively active mutant D9K was used as the positive control. 
All the combinatorial mutants showed a smaller number of foci compared to D9K. 
Especially, triple mutant D9K/E198A/D199A rarely formed foci. Statistical 
analysis was calculated by student t-test with statistical significance set at P<0.05 
(*). Numbers of foci derived from E198A/D199A and all the combinatorial 
mutants were compared with that of untransfected NIH3T3 cells and D9K, 
respectively. 
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              A) 
 
              B) 
 
Figure 19. Foci formation assay in the presence of inhibitors of intracellular 
signaling. 
A) There are no foci in the presence of all the inhibitors. 25 µM U-73122 was 
used for inhibition of Gαq-mediated PLC-β signaling, 100 µg/ml pertussis toxin 
(PTX) was for Gαi, and 50 µM AG490 was for Janus kinases-mediated signal 
transducer and activator of transcription 3 (STAT3) pathway. B) T-test showed 
that inhibitor-mediated reductions of constitutively activation of E198A/D199A 
and D9K/D199A mutant receptors are statistically significant (p < 0.05, *). 
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Chapter 5 Discussion 
 
An increasing number of studies have focused on the mechanism of 
receptor activation of GPCRs due to its importance as pharmacological targets 
(45, 132). Two major mechanisms for receptor activation including the ionic lock 
and toggle switch were found in rhodopsin and β2AR, whereas most of class A 
GPCRs do not contain these residues necessary for these mechanisms (38, 
133). Some including rhodopsin and β2AR showed the conservation of a Glu 
residue in the boundary of IC3 and TM6 to interact with the (D/E)R(Y/W) motif for 
receptor stabilization in the inactive state. CXCR2 also does not contain a 
conserved Glu residue for the ionic lock, suggesting CXCR2 undergoes an 
unknown mechanism for receptor activation. 
It has been shown that the amino terminus and second extracellular loop 
of CXCR2 is crucial for ligand recognition and receptor activation (80, 81, 83-88, 
124). Interestingly, a previous study of the EC2 of CXCR2 showed that a 
negatively charged residue, Asp199 is crucial to manage internalization speed of 
the receptor (84). Furthermore, another current investigation showed that single 
mutations (e.g. D9K and D9R) of Asp9 in the amino terminus of CXCR2 lead to 
constitutive activation (Park et al., unpublished). These observations suggest that 
charged residues in the second extracellular loop of GPCRs may play a role in 
receptor stabilization and activation.  
To study a role for EC2 in ligand binding, we generated single mutations in 
EC2, including the substitution of negatively charged residues including Glu198 
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and/or Asp199 and positively charged residues such as Arg184, Arg185, Arg208, 
and Arg212 to Ala residue to neutralize their charges. The Arg residues are also 
mutated to a charge-reversal residue, Asp residue. Like wild-type CXCR2, the 
mutant receptors were well expressed at the cell surface. However, all the 
mutant receptors except for D199A demonstrated no binding affinity for CXCL8. 
This result suggests that charged residues in EC2 of CXCR2 are crucial for 
ligand recognition, but do not affect cell surface expression.  
Furthermore, we designed two concepts, the attraction and repulsion 
models, to understand CXCR2 activation (Fig. 15). To end that, we constructed 
two different combinatorial mutation sets consisting of CAMs (D9K and D9R) and 
the substitutions in EC2. All the combinatorial mutant receptors were well 
expressed at the cell surface but had no CXCL8 binding affinity similar to most of 
the single mutations in EC2 of CXCR2. Interestingly, all the complementary 
charge-reversal mutants to prove the repulsion model (D9R/R184D, D9R/R185D, 
D9R/R208D, and D9R/R212D) showed no ligand binding affinity, inactivation of 
PLC-β3 and inhibition of cellular transformation. The mutants were expected to 
function like wild-type CXCR2 because some studies have generated charge-
reversal mutations to mimic the structural constraints of their wild-type receptors 
(135). However, unexpectedly, their structural constraints would not be the same 
with wild-type CXCR2, even though there is no problem in the protein folding of 
the mutant receptors (Table 4). Therefore, the mutant receptors would be 
constitutively inactive mutants (CIM) or dead receptors. On the other hand, 
another set of the combinatorial mutants (D9K/E198A, D9K/E198A, and 
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D9K/E198A/D199A) retained their constitutive activity via PLC-β3 signaling even 
though the mutants were unable to bind CXCL8.  
Interestingly, similar results were observed with charged residues in the 
extracellular loops of neurohyphophysical hormone receptors including 
vasopressin and oxytocin receptors (137). Using Ala mutations and charge-
reversal substitutions, some of the charged residues showed a significant 
reduction of ligand binding affinity, regardless of surface expression. The study 
also generated two complementary mutants including R46D/D204R and 
R125D/D204R to prove interaction between the mutated residues. However, the 
cell surface expression level of the combinatorial mutants was very low (≤20% 
fold over wild-type) and the binding affinities for their cognate ligands were 
significantly reduced or undetectable. 
Consistent with our result, it has been previously shown that Asp199 in 
EC2 of CXCR2 is not related to ligand binding (84). D199N showed a similar 
CXCL8 binding affinity to wild-type CXCR2 but D199V has a higher CXCL8 
binding affinity than wild-type CXCR2. Furthermore, the mutant receptors 
(D199N and D199V) had no effect on Ca2+ mobilization by CXCL1 or CXCL8 
stimulation. Similarly, in this study, D199A showed no difference in PLC-β3 
signaling, whereas E198A/D199A induced activation of PLC-β3. Previously, it 
was shown that negatively charged residues in EC2 of FFAR1 are important for 
receptor activation for constructing ionic locks to positively charged residues on 
distinct transmembranes (134). 
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Interestingly, E198A/D199A was identified as a novel constitutively active 
mutant via foci formation assays. Since many investigations have tried to 
construct site-directed or random mutagenesis of the EC2 of GPCRs (36), it 
would be the first CAM derived from double mutations of residues in EC2. The 
double mutant receptor might have structural constraints for CXCR2 activation, 
whereas the single mutations, E198A and D199A, allow themselves to have 
inactive forms. The negatively charged residues are very close to a highly 
conserved disulfide bond (Cys119-Cys196) linking EC2 and TM3. The special 
location of the two residues in EC2 might explain how the double mutation leads 
to constitutive activation. The neutralization (with Ala residue) of the residues 
might induce a structural change in TM3 through the disulfide bond. Furthermore, 
the substitution with Ala in combinatorial mutant receptors derived from the 
attraction models might promote breakdown of the structural constraints of CAM 
D9K.  
Unlike rhodopsin and β2AR, most of class A GPCRs including CXCR2 lack 
possible residues in IC3 for an ionic lock, pointing to the need to study possible 
other mechanisms for activation of GPCRs. Our observations might provide new 
insight to understand a role of extracellular regions (especially, amino terminus 
and EC2) in ligand binding and receptor activation. 
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PART IV CONCLUSIONS 
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Most chemokine receptors can be activated by more than one chemokine 
(77). CXC chemokine receptor 2 (CXCR2) binds multiple CXC chemokines 
including CXCL1 (GRO-α), CXCL2 (GRO-β), CXCL3 (GRO-γ), CXCL5 (ENA78), 
CXCL6 (GCP2), CXCL7 (NAP2), and CXCL8 (78, 79). Although CXCR1 and 
CXCR2 show over 75% amino acid identity, only CXCL6 and CXCL8 activate 
CXCR1, suggesting that the two chemokine receptors have different 
mechanisms for chemokine ligand binding (80). It has been shown that the amino 
terminus and second extracellular loop of CXCR2 is crucial for ligand recognition 
and receptor activation (80, 81, 83-88, 124). Interestingly, a previous study of the 
EC2 of CXCR2 showed that a negatively charged residue, Asp199, is crucial to 
manage internalization speed of the receptor (84). Furthermore, another current 
investigation showed that single mutations (e.g. D9K and D9R) of Asp9 in the 
amino terminus of CXCR2 led to constitutive activation (Park et al., unpublished). 
These observations suggest that charged residues in the second extracellular 
loop of GPCRs may play a role in receptor stabilization and activation. However, 
the mechanism of the ligand binding and receptor activation is still unknown.  
First, in our study, a CXCR2 structure is predicted on the basis of crystal 
GPCR structures including rhodopsin, β2AR, and CXCR4 by homology modeling 
(Fig. 10). The highly conserved motifs ((D/E)R(Y/W), NPXXY, toggle switch, and 
disulfide bonds found in sequence alignments of the template GPCRs were 
helpful to generate CXCR2 models (Fig. 7,8,9). Using Cα RMSDs, structural 
alignments of seven transmembrane domains showed individual models tend to 
be similar to their templates (Fig, 11). Modeling results indicated that the crystal 
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structure of CXCR4 might be the best template for CXCR2 prediction due to the 
relatively high identity (33.3% identity for CXCR4) in sequence alignments and 
the lowest RMSD values (0.78Å). Site Finder was used to predict ligand binding 
sites of b2AR-CXCR2 and CXCR4 (Fig. 12). The prediction suggests that 
residues in all the extracellular loops are highly associated with ligand binding. 
Residues in some of the transmembranes domains showed involvement in ligand 
binding as well. The second extracellular loop of the CXCR4-based homology 
modeled CXCR2 provided two β-strands like rhodopsin and CXCR4 and the 
prediction is very similar with results of the predictions from two web-based 
prediction programs, NPS@SOPMA and NetSurfP (Fig. 13). Superimposition of 
the second extracellular loops of CXCR4 and CXCR4-based CXCR2 suggested 
that the second extracellular loop of CXCR2 is structurally very similar with that 
of CXCR4 with below 2.0 Å RMSD. 
Furthermore, we studied solvent accessibility of residues in the second 
extracellular loop of CXCR2, a key region for ligand binding and receptor 
activation, in the inactive state of the receptor. MTSEA-biotin accessibility of 
substituted cysteine residues in the second extracellular loop was measured by 
immunostaining of FITC-streptavidin using flow cytometric analysis. The 
normalization of the accessibility was determined based on the cell surface 
expression level of the substituted cysteine mutant receptors (Fig. 14). Most of 
the residues in the second extracellular loop were found to be solvent accessible 
in the inactive state of CXCR2, indicating that the residues might be involved in 
ligand recognition. The results showed that all the charged residues except for 
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Arg208 in second extracellular loop also have solvent accessibility, pointing to 
possibility of ligand binding. However, 204TANWR208 residues showed no solvent 
accessibility, suggesting that they might be involved in the interaction with the 
amino terminus or other extracellular loops. Our finding of ligand binding sites for 
CXCR2 models also suggests that the most of the residues in the region could 
form a ligand binding pocket to contact its cognate ligands. 
Second, we studied the role of charged residues in EC2 of CXCR2 in 
ligand binding and receptor activation. Using constitutively active CXCR2 
mutants, D9K and D9R, a potential role of charged residues in the second 
extracellular loop of CXCR2 was investigated.  
Combinatorial mutations consisting of the constitutively active mutants in 
the amino terminus and single mutations of charged residues in the second 
extracellular loop were generated to study two concepts including “attraction” and 
“repulsion” model (Fig. 15). The mutant receptors were used to test their effects 
on cell surface expression, ligand binding, receptor activation through PLC-β3, 
and cellular transformation. All of the mutations in the repulsion model result in 
CXCR2 receptors that are unable to bind ligand, suggesting that all the Arg 
residues (Arg184, Arg185, Arg208, and Arg212) in the second extracellular loop 
are important for ligand recognition. Although charge-reversal complementary 
mutations in the repulsion model were expected to retain structural constraints of 
CXCR2, none of the mutant receptors function as wild-type CXCR2 in the 
inactive and active state (Fig. 16, 17). Interestingly, mutations in the attraction 
model partially inhibited receptor activation of constitutively active mutant D9K, 
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suggesting that Glu198 and Asp199 residues in the second extracellular loop are 
associated with receptor activation (Fig. 16, 18). Furthermore, a novel 
constitutively active mutant, E198A/D199A, was identified in this study (Fig. 16, 
18). These negatively charged residues are very close to a disulfide bond 
(Cys119-Cys196) linking the second extracellular loop and the third 
transmembrane.  
In Part II, the discoveries about the structural basis of CXCR2 and 
interdisciplinary approaches would provide new insights to investigate unknown 
mechanisms of interaction with its cognate ligands and receptor activation. These 
observations in Part III suggest the interaction between the amino terminus and 
EC2 of CXCR2 for ligand binding and receptor activation. Although crystallization 
studies of the amino terminus are limited for homology modeling and dynamic 
simulation (e.g. ligand docking), several groups have resolved the structures of 
the amino terminus in GPCRs using NMR, indicating that this approach with 
NMR would be effective and accurate to understand unknown amino terminus 
structures (138-140). Furthermore, some biochemical approaches including 
disulfide cross-linking, disulfide trapping, and protein digestion, would be helpful 
to discover unknown mechanism of ligand binding and receptor activation in 
GPCRs including CXCR2 (11, 139, 141, 142).  
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